NBER WORKING PAPER SERIES

EQUITY VESTING AND MANAGERIAL MYOPIA

Alex Edmans
Vivian W. Fang
Katharina A. Lewellen

Working Paper 19407
http://www.nber.org/papers/w19407

NATIONAL BUREAU OF ECONOMIC RESEARCH
1050 Massachusetts Avenue
Cambridge, MA 02138
September 2013

We are grateful to Timur Tufail and Ann Yih of Equilar for answering numerous questions about the data, and Francesca Cornelli, Francisco Gomes, Ralph Koijen, Luke Taylor and seminar participants at LBS, Minnesota, Sydney, UNSW, UTS, and Wharton for helpful comments. Edmans gratefully acknowledges financial support from the Jacobs Levy Equity Management Center for Quantitative Financial Research and the Wharton Dean's Research Fund. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.

Equity Vesting and Managerial Myopia
Alex Edmans, Vivian W. Fang, and Katharina A. Lewellen
NBER Working Paper No. 19407
September 2013
JEL No. G31,G34

ABSTRACT

This paper links the impending vesting of CEO equity to reductions in real investment. Existing studies measure the manager's short-term concerns using the sensitivity of his equity to the stock price. However, in myopia theories, the driver of short-termism is not the magnitude of incentives but their horizon. We use recent changes in compensation disclosure to introduce a new empirical measure that is tightly linked to theory - the sensitivity of equity vesting over the upcoming year. This sensitivity is determined by equity grants made several years prior, and thus unlikely to be driven by current investment opportunities. An interquartile increase is associated with a decline of 0.11% in the growth of R&D (scaled by total assets), 37% of the average R&D growth rate. Similar results hold when including advertising and capital expenditure. Newly-vesting equity increases the likelihood of meeting or beating analyst earnings forecasts by a narrow margin. However, the market's reaction to doing so is lower, suggesting that it recognizes CEOs' myopic incentives.

Alex Edmans
The Wharton School
University of Pennsylvania
2460 Steinberg Hall-Dietrich Hall
3620 Locust Walk
Philadelphia, PA 19104
and NBER
aedmans@wharton.upenn.edu

Vivian W. Fang
Carlson School of Management 3-109
321 19th Avenue S
Minneapolis, MN 55455
fangw@umn.edu

Katharina A. Lewellen
Tuck School at Dartmouth
100 Tuck Hall
Hanover, NH 03755
katharina.lewellen@tuck.dartmouth.edu

This paper studies the link between real investment decisions and the vesting horizon of a CEO's equity incentives. We find that research and development ("R&D") is negatively associated with the stock price sensitivity of stock and options that vest over the course of the same year. This association continues to hold when including advertising and capital expenditure in the investment measure. Moreover, CEOs with significant newly-vesting equity are more likely to meet or beat analyst consensus forecasts by a narrow margin. These results provide empirical support for managerial myopia theories.

Many academics and practitioners believe that managerial myopia is a first-order problem faced by the modern firm. While the 20th century firm emphasized cost efficiency, Porter (1992) argues that "the nature of competition has changed, placing a premium on investment in increasingly complex and intangible forms", such as innovation, employee training, and organizational development. However, the myopia theories of Stein (1988, 1989) show that managers may fail to invest due to concerns with the firm's short-term stock price. Since the benefits of intangible investment are only visible in the long run, the immediate effect of such investment is to depress earnings and thus the current stock price. Therefore, a manager aligned with the short-term stock price may turn down valuable investment opportunities.

Despite its perceived importance, myopia is very difficult to test empirically. Standard measures of CEO incentives (e.g., Hall and Liebman (1998)) quantify the sensitivity of managerial wealth to the stock price stemming from his stock and option compensation. However, in myopia models, the driver of short-termism is not the overall level of equity compensation, but the weighting of this compensation towards the short-term as opposed to long-term stock price (Stein (1988, 1989)). Equity that does not vest until the long term will deter rather than induce myopia (Edmans, Gabaix, Sadzik, and Sannikov (2012)).

However, operationalizing this theoretical concept empirically is tricky. The ideal experiment would be for the CEO to be forced to sell some equity for exogenous reasons, and to be aware of this forced sale ahead of time so that this expectation affects his actions. (This is indeed how short-term concerns arise in the Stein (1989) model). However, identifying sales that are both exogenous *and* predictable by the CEO is difficult. Unexpected forced sales (e.g., due to sudden liquidity needs) are likely exogenous, but typically unobservable by researchers and unpredictable by the CEO. Actual discretionary sales are observable to researchers, but likely endogenous for two reasons. First, omitted variables may drive both actual sales and investment. For example, the manager's negative private information on firm prospects may cause him both to sell equity and to reduce investment. Second, some actual sales (e.g., due to sudden liquidity needs) may have been unpredictable by the CEO. Thus, actual sales are a poor proxy for the ideal explanatory variable, predicted sales, leading to measurement error.

We measure a manager's myopic tendencies using the sensitivity of his stock and options that are scheduled to vest over the upcoming year. We show that this sensitivity is highly correlated with actual sales: in the absence of private information, a risk-averse manager should sell his equity upon vesting. However, while a CEO's actual sales are an endogenous decision, the amount of newly-vesting equity is largely driven by the magnitude and vesting horizon of equity grants made several years prior.[1] For the same reason, it is known to the CEO in advance. We identify the equity that is scheduled to vest in a given year using a recently-available dataset from Equilar. This dataset contains grant-by-grant information on an executive's options, including whether they are vested or unvested. We can thus identify at an individual grant level the number of options that switch from unvested to vested in a given year. This grant-level

[1] Gopalan, Milbourn, Song, and Thakor (2013) show that most vesting periods are between three and five years.

information allows us to calculate the delta of the vesting options, which captures the manager's incentive to inflate the stock price. Equilar also provides the number of vesting shares; since the delta of a share is 1, this number does not need to be decomposed into individual grants.

We use the sensitivity of newly-vesting equity in two ways. First, we employ it as the explanatory variable of interest, relating it to changes in several measures of long-term investment. Our primary measure is R&D scaled by total assets, but we also include advertising and two measures of capital expenditure. We control for determinants of investment opportunities and the firm's ability to finance investment, firm and year fixed effects, and other components of CEO compensation – for example, the CEO's unvested equity, his already-vested equity, and the standard components of salary and bonus.

We find a negative and significant relationship between nearly all measures of investment and the sensitivity of newly-vesting equity. For example, an interquartile increase in this sensitivity is associated with a 0.11 percentage point decline in the growth of R&D scaled by total assets, which corresponds to 37% of the average growth in R&D scaled by total assets, 2% of the average R&D-to-assets ratio, and an average decline in R&D of approximately $1 million per year. Our results suggest that firms reduce investment in years in which significant CEO stock and option holdings vest.

Newly-vesting equity is of interest as an explanatory variable, since boards may wish to take into account its link with investment when designing the optimal contract. Similarly, since boards know the amount of newly-vesting equity at the start of a year, they can predict the CEO's incentives to cut investment, and if needed, counteract them. A broader question is how investment responds to expected equity sales in general. As in the Stein (1989) model, such sales can stem from channels other than vesting equity – a CEO may voluntarily hold already-

vested equity as a long-term investment (e.g., in a family firm), subsequently sell equity to rebalance his portfolio, and anticipate such sales beforehand. Since actual equity sales are endogenous, our second use of newly-vesting equity is as an instrument for actual sales. The two properties of newly-vesting equity discussed earlier – its high correlation with equity sales and its determination by equity grants several years prior – are analogous to the relevance criterion and exclusion restriction. We find a negative relationship between instrumented equity sales and investment. An interquartile increase in equity sales is associated with a 0.25 percentage point decline in the growth of R&D scaled by total assets, 4.6% of the average R&D-to-assets ratio.

The negative association between investment and vesting equity (or instrumented equity sales) can arise from two channels. First, vesting equity could cause a decline in investment. Managers intending to sell equity reduce investment, to inflate earnings and thus the stock price. Second, there is no causal relationship but instead the link arises from an omitted variable – current investment opportunities – that our controls fail to capture. It may be that boards believe that vesting equity reduces the manager's investment incentives, and thus schedule equity to vest precisely when they forecast that investment opportunities will decline. This explanation requires boards to be able to forecast investment opportunities several years in advance. Note that it is still consistent with myopia theories: boards ensure that options do not vest while investment opportunities are strong because they believe that vesting equity induces myopia.

To provide further evidence of the first channel, we show that newly-vesting equity is associated with a higher likelihood that a firm meets the analyst consensus earnings forecast or beats it by a narrow margin. In contrast, vesting is unrelated to the likelihood of beating the forecasts by a wide margin, consistent with earnings manipulation being more likely when earnings are close to the forecast. These results support the idea that vesting equity increases the

CEO's stock price concerns, but not the alternative hypothesis that equity vesting is correlated with changes in investment opportunities.

Finally, we study the market's reaction to earnings announcements. Controlling for the earnings realization, the announcement return is significantly lower for firms with higher levels of vesting equity, perhaps because the market suspects that such firms have incentives to inflate earnings by cutting investment. This effect is especially strong for firms that meet or beat the forecast, suggesting that this outcome more likely stems from earnings inflation. These findings are consistent with the Stein (1989) "signal-jamming" equilibrium, where the market is efficient and recognizes managers' myopic behavior.

This paper is related to a long literature on managerial myopia. In addition to the theories already cited, other models include Miller and Rock (1985), Narayanan (1985), Bebchuk and Stole (1993), Bizjak, Brickley, and Coles (1993), Goldman and Slezak (2006), Edmans (2009), and Benmelech, Kandel, and Veronesi (2010). However, as previously noted, precisely testing these theories is difficult. McConnell and Muscarella (1985) document positive stock price reactions to the announcements of capital investments. This result is sometimes interpreted as evidence against myopia, but can also arise from selection: managers only pursue projects whose value can be clearly communicated to the market in the short-term and they know will enjoy a positive reaction. Graham, Harvey, and Rajgopal (2005) provide survey evidence that 78% of executives would sacrifice long-term value to meet earnings targets. Using standard measures of incentives that capture the CEO's sensitivity to the stock price but not his horizon, Cheng and Warfield (2005), Bergstresser and Philippon (2006), and Peng and Roell (2008) find a positive link with earnings management, but Erickson, Hanlon, and Maydew (2006) find no link with accounting fraud. These conflicting results may arise because, theoretically, it is the horizon

rather than level of incentives that induces myopia. Bushee (1998) relates R&D to the horizon of a firm's shareholders rather than managers.

A small number of papers do consider the vesting horizon of incentives. Kole (1997) is the first to describe vesting horizons, but does not relate them to outcome variables. Johnson, Ryan, and Tian (2009) show that already-vested stock is related to corporate fraud, but do not study real investment or upcoming vesting. Gopalan, Milbourn, Song, and Thakor (2013) are the first to systematically analyze the CEO's horizon, also using Equilar. They develop a new "duration" measure of incentives, which weights each equity grant by its vesting period. They show how it varies across industries and with firm characteristics, and link it to earnings management (but do not investigate real outcomes). In contrast, our goal is to study the link between myopia and investment, and so our measure of myopic incentives is designed to minimize its correlation with current investment opportunities. While duration is affected by equity grants in the current year, which are likely correlated with growth options, newly-vesting equity depends on grants made several years ago. Although we cannot claim that past grants are completely exogenous to current investment opportunities and thus make strong causal statements, they are less likely driven by current investment opportunities than current grants.[2] Finally, a contemporaneous paper by Ladika and Sautner (2013) shows that FAS 123R induced firms to accelerate the vesting period of options, and such accelerated vesting led to a reduction in capital expenditure. Our papers are complementary in that they employ different empirical strategies to investigate the link between vesting and investment, and find consistent results. While they focus on a one-time shock, we study vesting (or instrumented equity sales) within a panel of firms. This broader

[2] While we use vesting equity as an instrument for equity sales, Shue and Townsend (2013) use institutional features of multi-year grant cycles as an instrument for option grants. They study the different question of whether options induce risk-taking.

setting allows us to quantify the responsiveness of investment to expected equity sales, rather than the more specific question of how investment responds to changes in the probability of accelerating options. We also show how vesting equity is related to both the likelihood of beating earnings forecasts and the market's response to earnings announcements.

This paper is organized as follows. Section 1 describes the data, in particular our measure of myopic incentives. Section 2 presents the investment results, and Section 3 analyzes earnings announcements. Section 4 concludes.

1 Data and Empirical Specification

This section describes the calculation of the variables used in our empirical analysis; a detailed description is in Appendix A.

1.1 Data and Sample

Since the implementation of FAS 123R in 2006, companies are required to disclose grant-level (rather than merely aggregate-level) information on each stock and option award held by a top executive. For an option grant, firms disclose not only the exercise price and expiration date, which allows us to give each grant a unique identifier, but also details on whether the options are vested or unvested. In particular, it will split a grant into two if part of the grant is vested and part remains unvested. We can thus track the vesting of a CEO's options by studying changes in the numbers of vested and unvested options with the same exercise price and expiration date. Separately, Equilar directly reports the number of shares that vest in a given year.

Given the short time series over which grant-level vesting status is available, we require a wide cross-section to maximize power. While the data is available in Execucomp for the S&P 1500, we use Equilar as it covers all firms in the Russell 3000. The initial sample consists of

9,385 firm-CEO-years from 2006-2010.[3] After merging with financial statement data from Compustat and stock return data from the Center for Research in Security Prices (CRSP), and removing financial and utilities firms, we obtain the final sample of 2,047 firms and 6,730 firm-CEO-years (see Table 1, Panel A). The analysis of earnings forecasts uses the Institutional Brokers' Estimate System (I/B/E/S) database and covers 1,498 firms and 17,173 firm-quarters.

1.2 Measurement of vesting equity

We obtain the number of shares that vest in a given year directly using the variable "Shares Acquired on Vesting of Stock" for each year-CEO. Such vesting may come from previously restricted stock or Long-Term Incentive Plans ("LTIPs"). To calculate the number of newly-vesting options, we first collect information, grant-by-grant, on the exercise price (*EXERPRC*), expiration date (*EXPDATE*), and number of securities (*NUM*) for a given CEO's newly-awarded options in year *t+1* and his unvested options at the end of year *t* and year *t+1*. We group these options by *EXERPRC* and *EXPDATE* and infer the number of newly-vesting options from the following relationship:

$$NEWLYVESTINGOPTIONNUM\ (EXERPRC_p,\ EXPDATE_d)_{t+1} = UNVESTEDOPTIONNUM\ (EXERPRC_p,\ EXPDATE_d)_t + NEWLYAWARDEDOPTIONNUM\ (EXERPRC_p,\ EXPDATE_d)_{t+1} - UNVESTEDOPTIONNUM\ (EXERPRC_p,\ EXPDATE_d)_{t+1},$$

where *p* and *d* index the exercise price and expiration date for a given option grant, *NEWLYVESTINGOPTIONNUM* is the number of newly-vesting options for this exercise price-

[3] We have 53 firm-years in which we have 2 CEOs, due either to dual CEOs or a change of CEO during the year. In these cases, the firm-year observation appears twice, once for each CEO. The results are robust to deleting these observations or keeping the CEO with the higher incentives from newly-vesting equity.

expiration date pair, *UNVESTEDOPTIONNUM* is the number of unvested options for this pair, and *NEWLYAWARDEDOPTIONNUM* is the number of newly-awarded options for this pair.

Having identified the number of vesting securities, we then calculate their delta. The delta measures the dollar change in the value of a security for a $1 change in the stock price, and thus the manager's incentive to inflate the stock price. It equals the number of shares it is equivalent to, from an incentive standpoint. The delta of a share is 1; we calculate the delta of an option using the Black-Scholes formula. For options that vest in year *t+1*, we use the risk-free rate, volatility, expiration date, and dividend yield from Equilar, as of the end of year *t*. The rationale is that, when making his investment decisions at the start of year *t+1*, the CEO will take into account the delta of his options at the start of this year. If these are unavailable, we use the inputs associated with a firm's newly-awarded options in year *t+1* from Equilar, followed by year *t*'s inputs from ExecuComp (or year *t+1*'s if year *t*'s are missing), and by year *t*'s inputs from Compustat (or year *t+1*'s if year *t*'s are missing), in that order.[4] [5]

After summing across the deltas of all of the CEO's vesting stock and options, we multiply the aggregate delta by the stock price at the end of year *t*. We call the resulting measure "sensitivity", and it represents the dollar change in the value of a CEO's equity for a 1% change in the stock price (it is equivalent to the Hall and Liebman (1998) measure of incentives). While the delta represents the effective number of vesting shares, the sensitivity represents their

[4] As a robustness check, we use Equilar inputs in year *t*, followed by Execucomp inputs in year *t*, followed by Compustat inputs in year *t*, followed by Equilar inputs in year *t+1*, followed by Execucomp inputs in year *t+1*, followed by Compustat inputs in year *t+1*, in that order. The results are barely affected.

[5] If the Black-Scholes inputs cannot be located directly in any of the three databases, we fill in the missing volatility by calculating past three-year stock price volatility using the CRSP daily files, the missing risk-free rate with the Treasury Constant Maturity Rate with the closest term to a given option, and the missing dividend yield by calculating the past five-year average dividend yield using the Compustat annual files, whenever data permits. If the expiration date is missing from Equilar, we delete the option.

effective value. Thus, in contrast to delta, sensitivity is comparable across firms with different stock price levels, and immune to stock splits.[6]

We sum the sensitivities of newly-vesting stock ($NEWLYVESTINGSTOCK_{t+1}$) and options ($NEWLYVESTINGOPTION_{t+1}$) to create $NEWLYVESTING_{t+1}$, the total sensitivity of all newly-vesting securities in year $t+1$. We similarly calculate $ALREADYVESTEDSTOCK_t$, the sensitivity of stock that had already vested by the end of year t, and add this to $ALREADYVESTEDOPTION_t$ (analogously defined) to create $ALREADYVESTED_t$, the sensitivity of all vested securities. We do the same for unvested securities, to calculate the analogous variables $UNVESTEDSTOCK_t$, $UNVESTEDOPTION_t$, and $UNVESTED_t$. We then create $UNVESTEDADJ_t$, which equals $UNVESTED_t$ - $NEWLYVESTING_{t+1}$ and thus excludes securities that vest in year $t+1$; we set this variable to zero if it is negative.[7] Appendix B gives a sample calculation for one CEO-year.

NEWLYVESTING differs from the Gopalan et al. (2013) duration measure as it is determined by equity grants several years prior, as described in the introduction. Another difference is that the calculation of duration requires several additional assumptions. Equilar provides information on the vesting period of a particular equity grant, and whether the grant exhibits cliff- or graded-vesting. However, the designation of "graded vesting" could refer to straight-line vesting (e.g., a grant of 100 shares with a 5-year horizon vests at a rate of 20 shares per year), backloaded vesting (e.g., 20 shares vest in year 4 and 80 shares in year 5), or frontloaded vesting. Our *NEWLYVESTING* measure captures the actual (rather than expected) vesting of equity over the current year, and thus does not require an assumption on graded vesting schedules. Calculating

[6] Several empirical studies of CEO incentives call this sensitivity measure "delta". In option pricing, delta refers to the dollar change in the value of an option for a $1 change in the value of the underlying share, so we use "sensitivity" to refer to the dollar change in the value of an option for a 1% change in the underlying share.

[7] In rare cases, $NEWLYVESTING_{t+1}$ can be higher than $UNVESTED_t$ because some unvested options have been canceled during the year, rather than having vested. Equilar does not record such cancelations, but they are very rare.

duration also requires the vesting schedule for equity granted prior to 2006, since some of this equity will still be outstanding during our time period of 2006-10. Since vesting schedules are unavailable pre-2006, they also need to be estimated using assumptions.[8]

As our second measure of myopic incentives, we construct the ratio *MMRATIO*, which equals *NEWLYVESTING* divided by the sum of *NEWLYVESTING* and *UNVESTEDADJ*. This ratio measures the CEO's concerns for the stock price over the upcoming year relative to future years. One drawback of a ratio-based measure is that it does not take into account the amount of vesting equity and thus the magnitude of myopic incentives. For example, if the CEO has little unvested equity, then even a small dollar value of newly-vesting equity will lead to a large *MMRATIO* even though the CEO will gain little from myopia in dollar terms. Nevertheless, we include tests based on *MMRATIO* as a robustness check. Similarly, we calculate the ratio *MMRATIOALL*, which equals *NEWLYVESTING* divided by the sum of *NEWLYVESTING*, *UNVESTEDADJ*, and *ALREADYVESTED*, i.e., incentives derived from total equity holdings.

1.3 Measurement of investment

Having chosen our measure of managerial incentives, we next decide how to measure myopia. Theoretically, myopia is any action that increases current earnings at the expense of long-term value, but this cost cannot be observed immediately by the market. Our first measure is the fall in R&D (*ΔRD*), scaled by total assets. R&D is generally expensed and thus

[8] The *NEWLYVESTING* measure also has its disadvantages compared to duration. In particular, it focuses on only the equity that vests over the upcoming year, thus effectively treating a share that vests in 2 years as the same as a share that vests in 5 years. In contrast, the duration measure takes into account all of a CEO's equity grants and their respective (estimated) vesting periods. Thus, the duration measure is appropriate for estimating the CEO's overall horizon, the goal of Gopalan et al. (2013). Focusing on newly-vesting equity is appropriate for our setting as it is a sharper measure of incentives to act myopically in the current year. For example, consider CEO A who has 5 shares vesting in year 1 and 5 vesting in year 6; CEO B has 10 shares vesting in year 3. CEO B has a shorter overall duration, but A likely has higher incentives to cut investment in the current year.

immediately reduces earnings.[9] On the other hand, any value created by R&D only manifests in the long-term, and so it is difficult for the market to observe it immediately and incorporate it in the stock price. While many firms expense R&D separately on the income statement, and so the market can identify if an earnings increase was caused by a cut in R&D, the income statement can only report the level of R&D expenditure and not its quality (i.e., its impact on future cash flows). For example, it is not clear whether a cut in R&D is due to an increase in efficiency or myopia.[10] For these reasons, prior literature finds that managers view R&D cuts as a way to increase short-run earnings. Graham, Harvey, and Rajgopal (2005) report that 80% of managers would cut discretionary expenditure on R&D, advertising, and maintenance to meet an earnings target. Bushee (1998) finds that investors who trade on earnings induce managers to cut R&D to meet earnings targets. Bhojraj, Hribar, Picconi, and McInnis (2009) find that firms that beat analyst forecasts by reducing discretionary spending (such as R&D and advertising) enjoy a short-term increase in stock prices that is reversed in the long-run.[11]

In our final sample, 2,531 firm-CEO-years (37.6% of our sample) have missing R&D, because R&D is either included within Selling, General, and Administrative expenses ("SG&A") or indeed zero. Following Himmelberg, Hubbard, and Palia (1999), we set missing R&D values to zero. As a robustness check, we remove an observation if R&D is missing and the results (available upon request) are slightly stronger.

[9] The general rule for R&D costs under the Statement of Financial Accounting Standards ("SFAS") Rule 2 is that they are expensed because their future economic benefits are uncertain. However, exceptions exist. Tangible assets acquired for R&D activities that have alternative future uses can be capitalized, as can the costs of computer software that is to be sold, leased, or otherwise marketed, after the technological feasibility for the product is established.

[10] Cohen, Diether, and Malloy (2013) find that "the stock market appears unable to distinguish between "good" and "bad" R&D investment".

[11] These results are inconsistent with the hypothesis that a cut in R&D signals poor investment opportunities (Bebchuk and Stole (1993)). Any such effect would bias our tests against finding a positive association between R&D cuts and vesting equity.

Based on similar motivation, we also include the increase in advertising expenditure in the dependent variable, if available. Chan, Lakonishok, and Sougiannis (2001) provide evidence that both advertising and R&D might be underpriced by the market, suggesting that a cut in either expenditure could boost the short-term stock price. Since advertising expenditures are sometimes included within SG&A, they are often missing. Therefore, we do not study them alone but combine them with R&D to form *ΔRDAD*, the change in the sum of R&D and advertising expenditures, scaled by total assets. We set missing advertising expenditures to zero, but verify that the results are robust to removing an observation if both R&D and advertising expenditures are missing.

We also include the change in capital expenditure (*ΔCAPEX*) and total investment (*ΔCAPEXALL*), scaled by total assets. While *CAPEX* is taken directly from the cash flow statement, *CAPEXALL* is the increase in gross fixed assets from the balance sheet. The latter represents a more comprehensive measure as it captures investment not fully reflected on the cash flow statement, such as capitalized leases. For example, consider a firm that sells capital and then leases it back to raise cash. *CAPEXALL* calculated from the balance sheet will correctly reflect the fact that no disinvestment has occurred, since the capitalized lease will be reflected in gross fixed assets. However, *CAPEX* taken from the cash flow statement will reflect a large reduction in investment.

While capital expenditure is not directly expensed, it lowers earnings through raising depreciation. In addition, it is typically financed by reducing cash or taking on additional debt. This increases a firm's net interest expense, reducing earnings, and also worsens the firm's solvency ratios (such as net debt-to-EBITDA), which may enter into market valuations. As two additional measures, we consider the change in the sum of R&D, advertising, and capital

expenditure (*ΔRDADCAPEX* and *ΔRDADCAPEXALL*), which aggregates all of these "discretionary" expenditures.

We use "investment" as an umbrella term to encapsulate the six different measures of long-term behavior: *RD*, *RDAD*, *CAPEX*, *CAPEXALL*, *RDADCAPEX*, or *RDADCAPEXALL*. Since R&D and advertising have a more negative effect on current earnings, due to being fully expensed, the first two are our primary measures of investment.

1.4 Control variables

In addition to our measures of CEO incentives, we also include additional control variables that may drive investment in year *t+1*. We use the controls in Asker, Farre-Mensa, and Ljungqvist (2013), plus some further controls for the firm's investment opportunities and CEO compensation. The first five controls proxy for investment opportunities. Q_t is Tobin's Q at the end of year *t*, calculated as the market value of assets (market value of equity, plus liquidating value of preferred stock, plus book value of debt, minus balance sheet deferred taxes and investment tax credit) divided by the book value of assets, MV_t is the log of market equity[12] and $MOMENTUM_t$ is the firm's compounded market-adjusted monthly stock returns over the twelve months in year *t* calculated from CRSP. Following Asker et al. (2013), we include Q_{t+1} in addition to Q_t.[13] Our fifth proxy for investment opportunities is AGE_t, firm age.

The next three controls measure a firm's capacity to finance investment. $CASH_t$ is cash and short-term investments, $BOOKLEV_t$ is book value of short- and long-term debt, and $RETEARN_t$ is balance-sheet retained earnings. All variables are measured at the end of year *t* and deflated

[12] Asker et al. (2013) match private firms with public firms on industry and size to study the difference in matched firms' investment behaviour, and so do not further control for size. Since matching is not relevant for our setting, we include size as an additional control.

[13] Asker et al. (2013) show that their results are robust to using sales growth rates between year *t* and *t+1*, and *t-1* and *t*, as an alternative proxy for growth opportunities to Q_t and Q_{t+1}. Our results are similarly robust.

by total assets. We also include ROA_t, the return-on-assets ratio, calculated as net income divided by average total assets in year t. This variable proxies for both investment opportunities and the ability to finance investment. We also add $SALARY_t$ and $BONUS_t$, two other components of CEO compensation.

1.5 Descriptive statistics

Summary statistics for our sample firms are in Table 1, Panel B. Our key dependent variables are changes in investment scaled by lagged total assets. An average firm exhibits a 0.3% year-on-year change in R&D. This figure becomes 0.4% when adding advertising, and 1% when further adding capital expenditure inferred from the balance sheet.

The sensitivity of newly-vesting securities, *NEWLYVESTING* has a mean (median) of $3.6 million ($1.3 million), with a mean of $2.5 million ($1 million) coming from newly-vesting options (shares). The sample means for *MMRATIO* and *MMRATIOALL* are 0.43 and 0.12, respectively, and the medians are 0.39 and 0.09. The standard deviation of *NEWLYVESTING* is $6.4 million and the coefficient of variation (standard deviation divided by the mean) is 1.8. For comparison, this statistic is 0.7 when computed separately for each CEO and then averaged, suggesting significant within-firm variation in the *NEWLYVESTING* measure.[14]

2 Investment

2.1 Equity vesting

To test our hypothesis that newly-vesting equity is correlated with managerial myopia, we run the following panel regression (omitting the firm subscript for brevity):

[14] To obtain another estimate of the within-firm variation of *NEWLYVESTING*, we run a regression of *NEWLYVESTING* on firm fixed effects. The standard deviation of the residuals from this regression – our measure of within-firm variation – is $3.3 million compared to the sample standard deviation of $6.4 million.

$$\Delta INVESTMENT_{t+1} = \alpha + \beta_1 NEWLYVESTING_{t+1} + \beta_2 UNVESTEDADJ_t +$$

$$\beta_3 ALREADYVESTED_t + \gamma OTHER\_CONTROLS_t + \varepsilon_t, \qquad (1)$$

where $\Delta INVESTMENT_{t+1}$ is the change in one of the six investment variables from year *t* to *t+1*, scaled by total assets. We measure *NEWLYVESTING* over year *t+1*, the same time period over which *ΔINVESTMENT* is measured. The rationale is that, at the start of year *t+1*, the CEO knows (from his contract) the amount of equity that will vest over the course of that year, and so may cut investment accordingly. Our hypothesis is that $\beta_1 < 0$, i.e., the impending vesting of equity is associated with a fall in investment. As control variables we include $UNVESTEDADJ_t$, $ALREADYVESTED_t$, and $OTHER\_CONTROLS_t$, a vector of the additional controls described in Section 1.4. We do not have a clear prediction for the signs of β_2 and β_3. While unvested equity that will not vest for several more years will likely dissuade myopia, that which will vest soon after the upcoming year may have the opposite effect. We are unable to estimate the vesting period of unvested equity without additional assumptions. Laux (2012) shows theoretically that unvested equity may exacerbate myopia: the CEO takes short-term actions to avoid being fired, since termination will lead to the forfeiture of unvested equity. While already-vested equity could lead to short-termism since the CEO can often sell it at any time, the CEO may be voluntarily holding already-vested equity as a long-term investment (e.g., in his family firm).

Finally, we use firm fixed effects to control both for firm-level heterogeneity in investment opportunities and CEO preferences towards investment (e.g., certain CEOs may be more cautious or more overconfident than average), year fixed effects to control for common shocks to investment opportunities, and cluster standard errors at the firm level. The inclusion of firm fixed

effects means that our identification is based on the time-series variation in *NEWLYVESTING* within a firm, which is sizable as discussed in Section 1.5.

Table 2, Panel A presents the core result of the paper. It shows that impending vesting of equity is significantly negatively associated with growth in five of the six investment measures – all except *CAPEX*. These results are also economically significant. For example, an interquartile increase in *NEWLYVESTING* is associated with a 0.11 percentage point decline in *ΔRD* (the growth in R&D scaled by total assets), which corresponds to 37% of the average growth in R&D scaled by total assets, 2% of the average R&D-to-assets ratio, and an average decline in R&D of approximately $1 million per year based on the median total assets of $882m in our sample. To our knowledge, these results are the first to link newly-vesting equity to real investment decisions.

The coefficient on *UNVESTEDADJ* is insignificant in all specifications, consistent with the ambiguous effect of unvested equity on investment. *ALREADYVESTED* is positive and significant in two specifications, weakly consistent with the idea that managers may be holding onto already-vested equity as a long-term investment. The control variables load with the expected signs. Investment growth is positively related to investment opportunities, as measured by Tobin's Q, momentum, and negatively related to market equity and age. It is positively related to the firm's ability to fund investment, as measured by cash holdings, retained earnings, and (the negative of) book leverage. The return-on-assets ratio, which may proxy for both investment opportunities and investment, is also a positive determinant.

One potential concern with Table 2, Panel A is that $NEWLYVESTING_{t+1}$ is correlated with the stock price at the start of year *t+1*, and thus investment opportunities in year *t+1*. Such correlation stems from two sources. First, *NEWLYVESTING* is the delta of the CEO's vesting

equity multiplied by the stock price at the end of year *t*. The multiplication by the stock price is necessary to give an incentive measure that reflects the CEO's wealth gain from increasing the stock price by a given percentage (rather than dollar) amount and is thus comparable across firms with different stock prices. Without the multiplication, our results become stronger.[15] Second, the delta of the CEO's vesting options is itself increasing in the current stock price. As a result, increases in the stock price both reflect improvements in investment opportunities and augment *NEWLYVESTING*. Such a channel will lead to a positive correlation between *NEWLYVESTING* and investment, which is the opposite of what we find. In addition, Table 2, Panel A already includes the price-based controls Q_t, Q_{t+1}, $MOMENTUM_t$, and MV_t. In the Online Appendix, we conduct additional robustness checks to address any residual correlation. In Table OA1, Panel A, rather than using an option's actual delta (which depends on the stock price), we assume a delta of 0.7, which is the mean delta in our sample. In Panel B, we assume that all options are at-the-money, which removes the dependence of the estimated delta on the current stock price, but still allows for deltas to vary across firms according to volatility and other inputs. Both panels show that the results are barely affected.

In Table 2, Panel A, we have the level of $NEWLYVESTING_{t+1}$ on the right-hand side in addition to firm fixed effects. The regression thus studies whether investment falls from the previous year's level, when the level of newly-vesting equity is high relative to the firm mean. Alternatively, one could ask whether investment falls when the level of newly-vesting equity is high, relative to the previous year's level. In Panel B, we replace the levels of

[15] An alternative measure of incentives that is independent of the stock price would be to divide *NEWLYVESTING* by the firm's market capitalization, to give the CEO's effective equity stake in the firm as a percentage of shares outstanding (rather than as a dollar value), as in the Jensen and Murphy (1990) incentives measure. This measure captures the dollar change in the CEO's wealth for a $1 increase in firm value, and is thus not comparable across firms of different size: a $1 increase in firm value is much less significant in a large firm than in a small firm.

$NEWLYVESTING_{t+1}$, $UNVESTEDADJ_t$, and $ALREADYVESTED_t$ with $\Delta NEWLYVESTING_{t+1}$, $\Delta UNVESTEDADJ_t$, and $\Delta ALREADYVESTED_t$, the changes in these variables from the previous year. The results are very similar, with $\Delta NEWLYVESTING_{t+1}$ being significantly negatively related to the same five investment measures. We do not adopt this as the primary specification to preserve sample size, given the already short time series of our sample.

In Table 2, we control for *UNVESTEDADJ* and *ALREADYVESTED* by including them as additional regressors. An alternative specification is to use them to scale the *NEWLYVESTING* measure and have *MMRATIO* or *MMRATIOALL* as the key explanatory variable. As discussed in Section 1.2, scaling provides a useful robustness check but has two potential drawbacks. First, the scaled measures do not account for the amount of vesting equity and thus may not capture the magnitude of CEO incentives to boost the stock price. Second, the direction of the link between investment and *UNVESTEDADJ* and *ALREADYVESTED* is unclear. Unvested securities could indeed reduce myopia if they vest in 5 years, but increase it if they vest in 2 years. Thus, scaling by *UNVESTEDADJ* may weaken the explanatory power of *NEWLYVESTING* for investment. Nevertheless, we report regressions with the scaled measures as a robustness check.

In Table 3, Panel A, we run the following regression:

$$\Delta INVESTMENT_{t+1} = \alpha + \beta MMRATIO_t + \gamma OTHER\_CONTROLS_t + \varepsilon_t, \qquad (2)$$

We find that *MMRATIO* is significantly negatively related to changes in R&D, scaled by total assets. An interquartile increase in *MMRATIO* is associated with a 0.16% fall in ΔRD, 53% of the sample mean ΔRD and 3% of the sample mean *RD*. This result remains significant when adding changes in advertising but not capital expenditure to the dependent variable. The

findings of Table 3, when compared with Table 2, are consistent with our conjecture that a ratio is a less precise measure of a CEO's myopic incentives, and also with the idea that cutting R&D and advertising are more effective ways to inflate earnings. Panel B shows similar results using *MMRATIOALL* as the incentive measure. In Table OA2, Panels A-D, we show that the results are unchanged using a delta of 0.7 or assuming that options are at-the-money. Table OA2, Panels E-F repeat the analysis with a changes-on-changes specification and shows that they are again little affected.

The results of Tables 2 and 3 show a consistent negative relationship between newly-vesting equity and various measures of investment, supporting managerial myopia theories. However, we cannot make strong causal claims. Even though newly-vesting equity is determined by equity granted several years prior, we cannot rule out the hypothesis that boards of directors are able to forecast declines in investment opportunities several years in advance and schedule vesting periods to coincide with these declines, so that the CEO cannot sell equity while investment opportunities are strong. Under this alternative explanation, there is no direct causality from *NEWLYVESTING* to a decline in investment growth, but an omitted variable (the expectation of future investment opportunities) causes both. This explanation requires boards to be able to forecast investment opportunities several years in advance. We try to address this hypothesis with a long list of controls for observable time-variation in both investment opportunities and the ability to finance investment, firm fixed effects to control for firm-specific time-invariant unobservable drivers of these factors, and year fixed effects to control for aggregate time-varying unobservable drivers. However, we cannot control perfectly for factors that are both firm-specific and time-varying. Note that this alternative explanation is also consistent with myopia theories. If the board is deliberately timing the vesting period of equity

to coincide with a decline in investment opportunities, such behavior is consistent with the board recognizing that newly-vesting equity deters investment.

2.2 Equity sales

The analysis in Section 2.1 studies the responsiveness of investment to newly-vesting equity. A broader question is the responsiveness of investment to anticipated equity sales, which can stem from channels other than vesting. Indeed, in the Stein (1989) model, the manager's myopic incentives arise because he expects to sell equity soon, but the model is ambivalent about the cause of such sales. Anticipated equity sales could instead arise if a CEO voluntarily holds already-vested equity as part of a long-term investment, but later decides to sell it to rebalance his portfolio or meet an anticipated liquidity need (e.g., finance his children going to college). However, we cannot regress investment on actual equity sales because they are endogenous.

The choice of *NEWLYVESTING* as an independent variable in Section 2.1 was motivated by two reasons. First, the amount of newly-vesting equity is determined by equity grants made several years prior, and thus unlikely to be correlated with current investment opportunities. Second, newly-vesting equity is likely correlated with actual sales of equity, since a risk-averse CEO should sell a significant proportion of his equity when it vests. These two reasons are analogous to the exogeneity and relevance criteria for a valid instrument. Therefore, we now use *NEWLYVESTING* as a valid instrument for equity sales in a two-stage least squares ("2SLS") procedure. Since in our setting, the coefficient on the instrument is of interest in its own right, we report the reduced form regressions in Tables 2 and 3, in addition to the structural form regressions in Table 4 (discussed below).

We calculate *STOCKSOLD*, the dollar value of the actual equity sold by the CEO, from the Thomson Financial Insider Trading database, which is compiled from Form 4 filed with the SEC.

We aggregate the number of shares sold by the CEO during year t+1 and multiply the number by his firm's stock price at the end of year t. We classify an insider trade as "sale" if the transaction is flagged as "Disposition" in Table 1 of Form 4.

Table 4, Panel A shows that the sensitivity of newly-vesting equity is indeed highly correlated with the value of equity sales. *STOCKSOLD* has a Pearson (Spearman) correlation of 0.377 (0.393) with *NEWLYVESTING*, both significant at the 1% level. Panel B presents the results of the 2SLS regression, using *NEWLYVESTING* as the instrument. The left-hand side of the panel gives the first-stage results and, consistent with Panel A, shows that our instrument satisfies the relevance criterion: *NEWLYVESTING* is significantly related to *STOCKSOLD* at the 1% level. The right-hand side of the table presents the second-stage results. Consistent with the results of Tables 2 and 3, the fitted value for equity sales (*FIT_STOCKSOLD*) is significantly and positively associated with reductions in the same five measures of investment as Table 2, Panel A – all except *ΔCAPEX*. In terms of economic significance, an interquartile increase in *STOCKSOLD* is associated with a 0.25 percentage point decline in the growth of R&D scaled by assets, 84% of the average growth of R&D scaled by assets and 4.6% of the average R&D-to-assets ratio. Table OA3 presents the 2SLS results using a delta of 0.7 or assuming that options are at-the-money when calculating *NEWLYVESTING*, which are similar.

As with any instrumental variables approach, it is impossible to test the exclusion restriction for the validity of an instrument and so we cannot make strong causal claims. Similar to the results of Section 2.1, a causal interpretation requires us to believe that *NEWLYVESTING* is not correlated with an omitted variable that is also linked to investment.

3 Earnings Announcements

3.1 Meeting or beating analyst forecasts

If vesting equity increases the CEO's stock price concerns, he will try particularly hard to avoid announcing earnings per share (EPS) below analyst expectations, since doing so typically leads to a large price drop (Skinner and Sloan (2002)). Thus, the CEO should be particularly likely to beat the consensus forecast, either by cutting investment or by engaging in other myopic actions, such as managing discretionary accruals. (For brevity, we use the verb "beat" to refer to weakly beating analyst consensus, i.e., delivering earnings at or above the forecast.)

This section therefore investigates the link between newly-vesting equity and the likelihood that a firm beats the analyst consensus. Finding a positive link would provide further evidence – separate to that in Section 2 – that vesting equity is correlated with managerial myopia. Moreover, it would help distinguish between the two potential explanations for the results of Section 2. A positive link would be consistent with managers with significant vesting equity inflating earnings, potentially through reductions in investment, but cannot be explained by boards designing contracts so that equity vests when investment opportunities decline.

Figure 1 plots the frequency of the earnings surprise - the difference between reported earnings and analyst forecasts - separately for firms with *NEWLYVESTING* in the top and the bottom tercile of the sample. The number of quarters in which the reported EPS beats (misses) the mean analyst consensus forecast is markedly higher (lower) for firms in the top *NEWLYVESTING* tercile than those in the bottom tercile. The difference is greatest for earnings announcements that beat the forecast by a small margin, consistent with the manager's incentives to inflate earnings being strongest when the firm is close to missing the forecast; in contrast, earnings significantly above the forecast are more likely to reflect unexpectedly good performance. For example, for the bottom tercile of *NEWLYVESTING*, 9.5% of earnings

announcements beat the forecast by less than one cent. This figure is 12.0% for the top tercile, an increase of 25.8%.

We now investigate the link between vesting equity and the likelihood of beating consensus forecasts in a multivariate setting, running the following firm-quarter regression using quarterly earnings announcements:

$$BEAT_{t+1} = \alpha + \beta_1 NEWLYVESTING_{t+1} + \beta_2 UNVESTEDADJ_t + \beta_3 ALREADYVESTED_t + \gamma OTHER\_CONTROLS2_t + \varepsilon_t, \quad (3)$$

The regression is estimated on a panel of quarterly earnings announcements. The dependent variable ($BEAT_{t+1}$) is set to one for quarters in which the firm's reported EPS beats the mean analyst consensus. Analyst forecasts and reported EPS are taken from I/B/E/S. To calculate analyst consensus, we delete stale forecasts made at least 90 days prior to the fiscal quarter end, as is standard in the literature, and require a firm to have at least three analysts after this deletion. For each analyst, we take the most recent forecasts before the announcement.

We also rerun equation (3) using the dependent variables $BEATBELOW1_{t+1}$, which equals 1 if the firm beats the consensus forecast by 1 cent or less, and $BEATABOVE1_{t+1}$, which equals 1 if the firm beats the consensus forecast by more than 1 cent. We predict that the link between vesting and manipulation is especially strong for $BEATBELOW1_{t+1}$.

The key independent variable remains $NEWLYVESTING_{t+1}$. We control for the two additional incentive measures $UNVESTEDADJ_t$ and $ALREADYVESTED_t$, plus $OTHER\_CONTROLS2_t$, a vector of additional controls previously shown to affect the likelihood of beating earnings forecasts (e.g., Matsumoto (2002), Davis, Soo, and Trompeter (2009)). We

use Tobin's Q (*Q*), the log of the market value of equity (*MV*), return on assets (*ROA*), and firm age (*AGE*), as in the investment regressions. We also include *INSTIPCT*, institutional ownership as a percentage of total shares outstanding, from Thomson's CDA/Spectrum database (form 13F); *ALY_N*, the log of one plus the number of analysts covering the firm; *HORIZON*, the log of one plus the mean average forecasting horizon (the number of days between an analyst forecast date and the earnings announcement date), to measure forecast staleness; *ALY_DISP*, analyst forecast dispersion, the standard deviation of analyst forecasts scaled by the absolute value of the mean consensus forecast; and *POSUE* (positive seasonal unexpected earnings), a dummy variable that equals one if the reported EPS exceeds that of the same quarter in the prior fiscal year, and zero otherwise. We also include Fama-French 12-industry fixed effects.

Table 5 presents the results. The first column shows that *NEWLYVESTING* is positively related to the likelihood of beating analyst forecasts, and significant at the 10% level. Column (2) shows that *NEWLYVESTING* is more strongly related to *BEATBELOW1*, the likelihood of beating the analyst forecast by up to one cent, with the coefficient now significant at 5%. In contrast, column (3) shows that *BEATABOVE1*, the likelihood of beating the forecast by above 1 cent is unrelated to *NEWLYVESTING*. Table OA4 in the Online Appendix repeats the analyses of columns (2) and (3) using 2 cents and 3 cents as the cutoff, and finds similar results. Thus, our conclusion that vesting equity is correlated with the likelihood of beating earnings forecasts by a narrow margin but not by a wide margin, is not sensitive to our margin definition.

A potential alternative explanation for our results is reverse causality. Some of the manager's equity may exhibit performance-based vesting, and good earnings announcements

may cause the stock price to rise and trigger performance-based vesting conditions.[16] Gopalan et al. (2013) report that 35.3% of stock in the Equilar dataset exhibits performance-based vesting, compared with only 1.9% of options. Thus, the concern is significant for stock but not options. The summary statistics of Table 1, Panel B show that the mean (median) value of newly-vesting options is over 2.5 (5) times larger than the median value of newly-vesting stock. Thus, *NEWLYVESTING* is predominantly comprised of options, for which performance-based vesting is rare. Columns (4) and (5) of Table 5 provides a more systematic evaluation of this alternative explanation. It replaces *NEWLYVESTING* with the separate variables *NEWLYVESTINGSTOCK* and *NEWLYVESTINGOPTION*. Column (4) shows that newly-vesting equity is insignificantly related to the likelihood of beating analyst consensus by 1 cent, but newly-vesting options are significantly positive (albeit at the 10% level, as they only capture part of the CEO's myopic incentives). Thus, the positive relationship between vesting equity and narrowly beating earnings targets is not driven by performance-vesting stock. Finally, consistent with the earlier results, column (5) shows that *BEATABOVE1* is unrelated to both components of vesting equity.

Overall, the results of Table 5 show that vesting equity is positively associated with narrowly beating earnings forecasts, supporting the hypothesis that vesting causes managers to act myopically. While the tests do not prove that this causal effect drives the results in Section 2, they do narrow the range of admissible alternative explanations. Any one non-causal explanation would also have to explain why vesting equity is correlated not only with falls in investment but also with narrowly beating earnings forecasts.

[16] Note that performance-based vesting is not a plausible explanation for the investment results in Tables 2-4 because it suggests a positive relation between vesting and investment, contrary to our findings. Performance-based vesting is triggered after high stock returns, when investment opportunities are also likely to be high. (Moreover, all regressions in Tables 2-4 control for stock returns directly.) See Bettis, Bizjak, Coles, and Kalpathy (2010) for a systematic study of equity with performance-based vesting.

3.2 Market reaction to earnings announcements

The results of the paper thus far show that managers with significant vesting equity are more likely to reduce investment and narrowly beat earnings forecasts. We finally study the separate question of whether the market rationally takes into account such managers' myopic tendencies. In the Stein (1989) "signal-jamming" equilibrium, myopic managers cut investment to increase earnings in an attempt to inflate the stock price, but the market rationally discounts reported earnings and all firms are efficiently priced. Even though managers do not succeed in inflating the stock price, they remain trapped into engaging in myopia as the market discounts whatever earnings they report – thus, if they did not inflate earnings, the earnings would still be discounted and the firm would be underpriced. Hence, the market is efficient and managers inefficiently underinvest. An alternative scenario is where the market does not take into account managers' myopic tendencies – either because it lacks information on the manager's incentives, or because it has information but is inefficient – and so does not discount reported earnings.

We distinguish between these two scenarios by studying how the market's reaction to earnings announcements depends on the level of vesting equity. It is well-established that the market reaction to an earnings announcement is increasing in the surprise, with a discontinuity at zero: beating the forecast leads to a markedly higher reaction than missing it (Bartov, Givoly, and Hayn (2002)). We study whether, controlling for the earnings surprise, the market's response is less positive for CEOs with significant vesting equity, because it places a probability that such CEOs have inflated their earnings. We run the following regression:

$$CAR_{t+1} = \alpha + \beta_1 NEWLYVESTING_{t+1} + \beta_2 UNVESTEDADJ_t + \beta_3 ALREADYVESTED_t +$$

$$\gamma_1 BEAT_{t+1} + \gamma_2 NEWLYVESTING_{t+1} \times BEAT_{t+1} + \gamma_3 DIF_{t+1} + \delta OTHER\_CONTROLS3_t + \varepsilon_t, \quad (4)$$

CAR_{t+1} is the (-1, +1) three-day market-adjusted return to a quarterly earnings announcement in year *t+1*, which is also the year for which we measure vesting equity ($NEWLYVESTING_{t+1}$). In our previous regressions, the dependent variable was a *t+1* decision affected by the manager, such as investment or earnings, and the manager knows $NEWLYVESTING_{t+1}$ at the time of his decision since he observes his own contract. Here, it is investors who determine announcement returns, and they will typically be unable to calculate $NEWLYVESTING_{t+1}$ using our methodology until the year *t+1* proxy statement is disclosed. FAS 123R only requires firms to disclose the proportions of an individual equity grant that are vested and unvested, but not the vesting schedule of unvested equity. However, in some cases, firms voluntarily disclose the precise vesting schedule of each equity grant in their proxy filings – i.e., the filings contain additional information not in Equilar – so that the market can calculate $NEWLYVESTING_{t+1}$ accurately before the beginning of year *t+1*. For firms that only disclose the required minimum, the market can estimate $NEWLYVESTING_{t+1}$ from previous proxy statements using certain assumptions (see Gopalan et al. (2013) for a possible methodology). To account for this, we divide the equity variables $NEWLYVESTING_{t+1}$, $UNVESTEDADJ_t$, and $ALREADYVESTED_t$ into terciles and use the ranks instead of the raw variables in the regressions. This specification assumes that the market can estimate which tercile of vesting equity a firm will fall into, even though it may be unable to predict exactly where within a tercile it will fall. Our results remain robust to using quintiles or deciles.

The regressions also include the same $BEAT_{t+1}$ dummy variable used earlier, which in some specifications we interact with $NEWLYVESTING_{t+1}$, and DIF_{t+1}, the earnings surprise (difference between the actual and forecast earnings). *OTHER_CONTROLS3* is a vector of control variables previously shown to be correlated with announcement returns, taken predominantly from Savor and Wilson (2011). *LEVERAGE* is the ratio of total debt to the sum of total debt and book equity. *PASTRET(1Y)* is the cumulative monthly industry-adjusted return over the year prior to the announcement and *PASTRET(1M)* is the industry-adjusted return in the month prior to the announcement. We include *FYE*, a dummy variable for the last quarter of a fiscal year, because the Q4 earnings announcement sometimes coincides with the release of a proxy statement. We include *ANNRET(LAG1)*, *ANNRET(LAG2)*, *ANNRET(LAG3)*, and *ANNRET(LAG4)*, earnings announcement returns for quarters -1 to -4 relative to the current quarter, to control for serial correlation in announcement returns (Abarbanell and Bernard (1992)). We include industry fixed effects and cluster standard errors by announcement day.

Table 6 presents the results. Column (1) omits the explanatory variables involving *BEAT* and *DIF*, i.e., does not control for the magnitude of the earnings announcement. *NEWLYVESTING* is negative and insignificant, suggesting that the market does not respond more positively to earnings announcements from CEOs with more vesting equity. In combination with Table 5, column (1) suggests that, while such CEOs are more likely to report earnings at or above analyst expectations, the market does not respond any more favorably to such reports, potentially because it expects that they have been inflated. Column (2) adds *BEAT* and *DIF* as additional regressors, to control for the actual announcement. Consistent with the literature, *BEAT* is positive and highly significant. However, *NEWLYVESTING* is now significantly negative: holding constant the earnings surprise, the market responds less positively to the earnings

announcement if the CEO has significant newly-vesting equity, suggesting a higher perceived probability that the earnings have been inflated. Increasing the *NEWLYVESTING* tercile rank by one lowers the earnings announcement return by 0.28 percentage points.

Column (3) adds an interaction term between *BEAT* and *NEWLYVESTING*. This interaction term is significantly negative. Thus, the negative association between *NEWLYVESTING* and announcement returns documented in column (2) is driven by quarters in which earnings exceed the analyst forecast, consistent with the market expecting more earnings inflation when earnings surprises are positive. Increasing the *NEWLYVESTING* tercile rank by one lowers the market response to beating a forecast by 1.22 percentage points, versus the average response of 2.46%.

It is interesting to note that the coefficient on *NEWLYVESTING* is now positive. It implies that increasing the *NEWLYVESTING* tercile by one mitigates the negative reaction to missing an earnings forecast by 0.5 percentage points compared to the baseline of -3.6%. One potential interpretation is that the market infers that the manager has not inflated earnings, despite his myopic incentives, and that this inference mitigates the negative response to missing the analysts' forecast.

In sum, we find that, although managers with more vesting equity are more likely to beat earnings forecasts, doing so does not lead to a more positive market response on average. Controlling for the earnings surprise, the announcement returns are lower for higher newly-vesting equity, especially in quarters in which earnings exceed the forecast. These findings suggest that the stock market recognizes managers' incentives to inflate earnings when a significant amount of their equity vests.

4 Conclusion

This paper studies the link between equity vesting and real investment decisions. We construct a new empirical measure of a CEO's myopic incentives that corresponds closely to managerial myopia theories: the sensitivity of equity vesting over the next year. This measure contrasts standard measures of CEO incentives which gauge the manager's sensitivity to the stock price, but do not consider the horizon. We demonstrate that newly-vesting equity is significantly negatively related to R&D, and the results remain significant when including other discretionary spending such as advertising and capital expenditure. We also use newly-vesting equity as an instrument to estimate the responsiveness of investment to anticipated stock sales in general.

Vesting equity is positively related to the likelihood of beating analysts' quarterly earnings forecasts. However, the market responds less positively to beating analyst consensus if the manager has significant vesting equity, implying that it takes his myopic incentives into account. Thus, such managers do not enjoy higher announcement returns overall. In sum, our results show that the *horizon* of managerial incentives is associated with myopia: managers with newly-vesting equity are more likely to cut investment, potentially to meet short-term earnings targets.

While we have shown that investment is negatively related to newly-vesting equity, we have not shown that the reduction in investment is inefficient. It may be that managers always overinvest due to empire-building tendencies, and so the fall in investment brings it closer to the optimal level. Laux (2012) shows that short-term projects may be optimal as they provide early feedback on CEO quality and guide interim replacement decisions. Even if the reduction in investment induced by the CEO's contract is inefficient, this does not mean that his contract is inefficient overall. Boards of directors may recognize that short-vesting equity leads to

underinvestment, but trade this off against the costs of long-vesting equity. For example, long-vesting equity exposes the manager to risks outside his control, and causes him to demand a risk premium.

More generally, our measure of myopic incentives, the sensitivity of stock and options vesting over the upcoming year, is relatively easy to construct, and potentially usable in wider contexts than investment decisions. For future research, it would be interesting to study whether it is linked to other examples of myopic behavior.

Appendix A: Definition of variables

This appendix describes the calculation of variables used in the core analysis. Underlined variables refer to variable names within Compustat.

Variable	Definition
CEO incentives from equity vesting	
$NEWLYVESTING_{t+1}$	The dollar change in the value of newly-vesting securities in year *t+1* for a 1% change in the stock price, calculated as *NEWLYVESTINGSTOCK* (the number of newly-vesting shares in year *t+1* × stock price at the end of year *t*) plus *NEWLYVESTINGOPTION* (aggregated delta of newly-vesting options in year *t+1* × stock price at the end of year *t*). Delta of an option is calculated using the Black-Scholes formula. The inputs (i.e., dividend yield, risk-free interest rate, and volatility) to the Black-Scholes formula are those associated with a firm's newly-awarded options in year *t* from Equilar, and if unavailable, replaced with those associated with a firm's newly-awarded options in year *t+1* from Equilar, followed by year *t*'s inputs from ExecuComp (or year *t+1*'s if year *t*'s are missing), and by year *t*'s inputs from Compustat (or year *t+1*'s if year *t*'s are missing), in that order;
$UNVESTED_t$	The dollar change in the value of unvested securities in year *t* for a 1% change in the stock price, calculated as *UNVESTEDSTOCK* (the total number of unvested share including unvested LTIP shares × stock price, both at the end of year *t*) plus *UNVESTEDOPTION* (aggregated delta of unvested options × stock price, both at the end of year *t*). Delta is calculated similarly as above;
$UNVESTEDADJ_t$	The sum of max ($UNVESTEDSTOCK_t$ - $NEWLYVESTINGSTOCK_{t+1}$, 0) and max ($UNVESTEDOPTION_t$ - $NEWLYVESTINGOPTION_{t+1}$, 0);
$ALREADYVESTED_t$	The dollar change in the value of already-vested securities in year *t* for a 1% change in the stock price, calculated as *ALREADYVESTEDSTOCK* (the number of already-vested shares × stock price, both at the end of year *t*) plus *ALREADYVESTEDOPTION* (aggregated delta of already-vested options × stock price, both at the end of year *t*). Delta is calculated similarly as above;
$MMRATIO_t$	The ratio of $NEWLYVESTING_{t+1}$ to the sum of $NEWLYVESTING_{t+1}$ and $UNVESTEDADJ_t$;
$MMRATIOALL_t$	The ratio of $NEWLYVESTING_{t+1}$ to the sum of $NEWLYVESTING_{t+1}$, $UNVESTEDADJ_t$, and $ALREADYVESTED_t$;
Stock sold	
$STOCKSOLD_{t+1}$	The number of shares sold in year *t+1* × stock price at the end of year *t*;
Change in investment	
ΔRD_{t+1}	Change in R&D expenditures (<u>*XRD*</u>) from year *t* to *t+1*, scaled by total assets (<u>*AT*</u>) at the end of year *t*. Missing R&D expenditures are set to zero;
$\Delta RDAD_{t+1}$	Change in the sum of R&D expenditures (<u>*XRD*</u>) and advertising expenses (<u>*XAD*</u>) from year *t* to *t+1*, scaled by total assets at the end of year *t*. Missing R&D expenditures and advertising expenses are set to zero;
$\Delta CAPEX_{t+1}$	Change in capital expenditures (<u>*CAPEX*</u>) from year *t* to *t+1*, scaled by total assets at the end of year *t*. Missing capital expenditures are set to zero;
$\Delta RDADCAPEX_{t+1}$	Change in the sum of R&D expenditures (<u>*XRD*</u>), advertising expenses (<u>*XAD*</u>), and capital expenditures (<u>*CAPEX*</u>) from year *t* to *t+1*, scaled by total assets at the end of year *t*. Missing R&D expenditures, advertising expenses, and capital expenditures are set to zero;

$\Delta CAPEXALL_{t+1}$ Change in annual increase in gross fixed assets (*PPEGT*) from year *t* to *t+1* (i.e.,($PPEGT_{t+1}$- $PPEGT_t$) - ($PPEGT_t$- $PPEGT_{t-1}$)), scaled by total assets at the end of year *t*. Missing *PPEGT* are replaced with net fixed assets (*PPENT*) if available;

$\Delta RDADCAPEXALL_{t+1}$ Change in the sum of R&D expenditures (*XRD*), advertising expenses (*XAD*), and change in annual increase in gross fixed assets (*PPEGT*) from year *t* to *t+1*, scaled by total assets at the end of year *t*. Missing R&D expenditures and advertising expenses are set to zero and missing *PPEGT* replaced with *PPENT* if available;

Control variables

Q_{t+1} Tobin's Q at the end of year *t+1*, calculated as [market value of equity (*PRCC_F*×*CSHPRI*) plus liquidating value of preferred stock (*PSTKL*) plus book value of debt (*DLTT*+*DLC*) minus balance sheet deferred taxes and investment tax credit (*TXDITC*)] divided by total assets (*AT*) at the end of year *t*.

Q_t Tobin's Q at the end of year *t*;

MV_t Natural logarithm of market value of equity at the end of year *t* (*PRCC_F*× *CSHPRI*);

$MOMENTUM_t$ A firm's compounded market-adjusted monthly stock returns over the twelve months in year *t*, with market-adjusted monthly stock return calculated as the firm's monthly raw stock return minus the corresponding monthly return on the CRSP value-weighted index;

AGE_t Natural logarithm of one plus a firm's age, approximated by the number of years listed on Compustat, as the end of year *t*;

$CASH_t$ Cash and short-term investments *(CHE)* at the end of year *t* divided by total assets at the end of year *t*;

$BOOKLEV_t$ Book value of debt (*DLTT*+*DLC*) at the end of year *t* divided by total assets at the end of year *t*;

$RETEARN_t$ Balance sheet retained earnings (*RE*) at the end of year *t* divided by total assets at the end of year *t*;

ROA_t Return-on-assets ratio, calculated as net income (*NI*) during year *t* divided by the average total assets of year *t*;

$SALARY_t$ CEO's salary in year *t*;

$BONUS_t$ CEO's cash bonus in year *t*;

Additional variables used in the analyst analysis

$BEAT_{t+1}$ A dummy variable that equals one if the reported EPS is more than or equal to mean analyst consensus forecast in a given quarter and zero otherwise;

$BEATBELOW1_{t+1}$ A dummy variable that equals one if the reported EPS falls between mean analyst consensus forecast and that plus 1 cent in a given quarter;

$BEATABOVE1_{t+1}$ A dummy variable that equals one if the reported EPS exceeds mean analyst consensus forecast plus 1 cent in a given quarter;

MV_t Natural logarithm of market value of equity (*PRCC_F*×*CSHPRI*) in $ millions at the end of year *t*;

$INSTIPCT_t$ The total percentage of shares owned by institutional investors at the end of the 4^{th} quarter of year *t*;

ALY_N_{t+1} Natural logarithm of one plus the number of analysts;

$HORIZON_{t+1}$ Natural logarithm of one plus the mean average forecasting horizon, with forecasting horizon calculated as the number of days between an analyst forecast date and earnings announcement date;

ALY_DISP_{t+1}	Analyst forecast dispersion, calculated as the standard deviation of analyst forecasts scaled by the absolute value of the mean analyst consensus forecast;
$POSUE_{t+1}$	A dummy variable that equals one if the reported EPS in a given quarter exceeds that of the same quarter last fiscal year and zero otherwise;
Additional variables used in the earnings announcement analysis	
CAR_{t+1}	Cumulative market adjusted return from day -1 to +1 around the quarterly earnings announcement in year *t+1*. Market adjusted daily returns are computed by subtracting from the stock' raw return the return on the CRSP value-weighted NYSE/AMEX/NASDAQ index;
DIF_{t+1}	Difference between the reported EPS and the mean analyst consensus forecast;
$LEVERAGE_t$	Sum of long-term and short-term debt divided by the sum of the short-term and long term debt, and the book value of equity;
PASTRET(1Y)	Cumulative monthly industry adjusted return over the twelve month prior to the earnings announcement in percent;
PASTRET(1M)	Monthly industry adjusted return for the month prior to the earnings announcement in percent;
FYE	A dummy variable to indicate the 4^{th} quarter of a fiscal year;
ANNRET(LAG1-4)	Cumulative market adjusted returns from day -1 to +1 around the quarterly earnings announcements in the quarters -1 to -4 relative to the current quarter. The computation is the same as for the current quarter.

Appendix B: A numerical example

This appendix illustrates the calculation steps to derive equity incentives for one CEO in our sample, along with the company's disclosure tables retrieved from Equilar for the two fiscal years on which the calculations are based. As an example, we use James McCann, CEO of 1-800 Flowers.com, Inc. and calculate the stock price sensitivity of his newly-vesting securities for the fiscal year ended on June 30th, 2009 (*NEWLYVESTING*), that of his unvested securities for the fiscal year ended on June 30th, 2008 (*UNVESTED*), and that of his already-vested securities for the fiscal year ended on June 30th, 2008 (*ALREADYVESTED*).

First, we obtain option data from Equilar for James McCann:

B.1 Outstanding options as reported in Equilar

	Equity Type	Number of Securities	Exercise Price	Expiration Date
	As of June 30th, 2009			
(1)	Unexercisable Options	10,000	$ 8.45	12/2/14
(2)	Unexercisable Options	20,000	$ 6.52	10/13/15
(3)	Unexercisable Options	224,109	$ 3.11	5/5/16
(4)	Exercisable Options	39,810	$ 12.44	12/17/09
(5)	Exercisable Options	82,730	$ 11.58	8/2/11
(6)	Exercisable Options	200,000	$ 12.87	1/11/12
(7)	Exercisable Options	200,000	$ 6.42	9/23/12
(8)	Exercisable Options	170,148	$ 6.70	3/24/13
(9)	Exercisable Options	29,852	$ 6.70	3/24/13
(10)	Exercisable Options	40,000	$ 8.45	12/2/14
(11)	Exercisable Options	30,000	$ 6.52	10/13/15
	As of June 30th, 2008			
(12)	Unexercisable Options	20,000	$ 8.45	12/2/14
(13)	Unexercisable Options	30,000	$ 6.52	10/13/15
(14)	Exercisable Options	39,810	$ 12.44	12/17/09
(15)	Exercisable Options	82,730	$ 11.58	8/2/11
(16)	Exercisable Options	200,000	$ 12.87	1/11/12
(17)	Exercisable Options	200,000	$ 6.42	9/23/12
(18)	Exercisable Options	170,148	$ 6.70	3/24/13
(19)	Exercisable Options	29,852	$ 6.70	3/24/13
(20)	Exercisable Options	30,000	$ 8.45	12/2/14
(21)	Exercisable Options	20,000	$ 6.52	10/13/15

B.2 Newly granted options as reported in Equilar

	Equity Type	Grant Date	Number of Securities	Exercise Price	Expiration Date
(22)	Newly Granted Options	5/5/09	224,109	$ 3.11	5/5/16

To calculate the number of newly-vesting options for fiscal year 2009 and unvested/already-vested options at the end of fiscal year 2008, we match and group the outstanding options by exercise price (*EXERPRC*) and expiration date (*EXPDATE*). We then infer the number of newly-vesting options from the following relationship:

$NEWLYVESTINGOPTIONNUM\ (EXERPRC_p,\ EXPDATE_d)_{t+1} = UNVESTEDOPTIONNUM\ (EXERPRC_p,\ EXPDATE_d)_t + NEWLYAWARDEDOPTIONNUM\ (EXERPRC_p,\ EXPDATE_d)_{t+1} - UNVESTEDOPTIONNUM\ (EXERPRC_p,\ EXPDATE_d)_{t+1}$

After identifying the number of newly-vesting, unvested, and already-vested securities, we then input into the Black-Scholes formula the risk-free rate, volatility, and dividend yield from Equilar and calculate each option's delta, grant-by-grant. The risk-free rate is not available for fiscal year 2008, so we replace it with the risk-free rate of 0.027 from fiscal year 2009. Similarly, we replace the missing volatility and dividend yield for fiscal year 2008 with the volatility of 0.7237 and the dividend yield of 0 from fiscal year 2009.

B.3 Calculated number and delta of newly-vesting, unvested, and already-vested options

Calculated number of options	Equity Type	Number of Securities	Exercise Price	Expiration Date	Term as of 6/30/08	Z	Delta
As of June 30th, 2009							
(12) - (1)	Newly-vesting Options	10,000	$ 8.45	12/2/14	6.4275	0.865	8,064
(13) - (2)	Newly-vesting Options	10,000	$ 6.52	10/13/15	7.2904	1.072	8,582
(22) - (3)	Newly-vesting Options	0	$ 3.11	5/5/16			
							∑Delta=16,646
As of June 30th, 2008							
(12)	Unvested Options	20,000	$ 8.45	12/2/14	6.4275	0.865	16,128
(13)	Unvested Options	30,000	$ 6.52	10/13/15	7.2904	1.072	25,746
							∑Delta=41,874
(14)	Already-vested Options	39,810	$ 12.44	12/17/09	1.4659	-0.266	15,724
(15)	Already-vested Options	82,730	$ 11.58	8/2/11	3.0904	0.242	49,266
(16)	Already-vested Options	200,000	$ 12.87	1/11/12	3.5344	0.243	119,174
(17)	Already-vested Options	200,000	$ 6.42	9/23/12	4.2356	0.825	159,041
(18)+(19)	Already-vested Options	200,000	$ 6.70	3/24/13	4.7342	0.844	160,152
(20)	Already-vested Options	30,000	$ 8.45	12/2/14	6.4275	0.865	24,192
(21)	Already-vested Options	20,000	$ 6.52	10/13/15	7.2904	1.072	17,164
							∑Delta=544,714

To calculate the price-sensitivity measures of options, we multiply the deltas calculated above by the closing stock price of $6.45 at the end of fiscal year 2008. James McCann's *NEWLYVESTINGOPTION* during fiscal year 2009 is therefore calculated as 16,646 × 6.45 = 107,366.7, and his *UNVESTEDOPTION* and *ALREADYVESTEDOPTION* at the end of fiscal year 2008 as 41,874 × 6.45 = 270,087.3 and 544,714 × 6.45 = 3,513,405.3, respectively.

Second, we obtain share data from Equilar for James McCann:

B.4 Shares held as reported in Equilar						
Shares Acquired on Vesting of Stock for the year ended on June 30th 2009 (a)	**Total Unvested Shares for the year ended on June 30th 2008 (b)**	**Total Unvested IP Shares for the year ended on June 30th 2008 (c)**	**Unvested Shares for the year ended on June 30th 2008 = (b) + (c)**	**Shares Held for the year ended on June 30th 2008 (d)**	**Options Exercisable Within 60 Days of Proxy Date for the year ended on June 30th 2008 (e)**	**Already-vested Shares for the year ended on June 30th 2008 = (d) – (e)**
67,434	33,000	277,677	310,677	36,775,359	792,540	35,982,819

To calculate the price-sensitivity measures of shares, we multiply the number of shares above by the closing stock price of $6.45 at the fiscal year end of 2008. James McCann's *NEWLYVESTINGSTOCK* during fiscal year 2009 is therefore calculated as 67,434 × 6.45 = 434,949.3, and his *UNVESTEDSTOCK* and *ALREADYVESTEDSTOCK* at the end of fiscal year 2008 as 310,677 × 6.45 = 2,003,866.65 and 35,982,819 × 6.45 = 232,089,182.55, respectively.

Finally, we sum the sensitivity measures of options and shares to construct the variables used in the main specification, *NEWLYVESTING*, *UNVESTEDADJ*, *ALREADYVESTED*, *MMRATIO*, and *MMRATIOALL*.

B.5 Variables used in the main specification				
NEWLYVESTING	***UNVESTEDADJ***	***ALREADYVESTED***	***MMRATIO***	***MMRATIOALL***
542,316	1,731,637.95	235,602,587	0.238	0.002

Table 1: Sample selection and summary statistics
Panel A: Sample selection

Firm-CEO-years from Equilar for which we can calculate newly-vesting securities in year *t+1*, and unvested and already-vested securities in year *t* for the sample period of fiscal year 2007 to 2010	9,385
(-) Observations missing COMPUSTAT data to calculate investment measures and control variables, and observations missing CRSP monthly returns to calculate momentum	(320)
(-) Observations associated with financial firms (SICs between 6000 and 6999)	(2,010)
(-) Observations associated with utility firms (SICs between 4900 and 4949)	(325)
Number of Firm-CEO-years in the final sample	6,730
Number of unique firms in the final sample	2,047

Table 1 (Cont'd)

Panel B: Summary statistics

Variable	N	Mean	SD	5%	25%	Median	75%	95%
CEO incentives from equity vesting								
$NEWLYVESTINGSTOCK_{t+1}$	6,730	1,007,672	2,203,651	0	0	127,564	926,250	5,142,500
$NEWLYVESTINGOPTION_{t+1}$	6,730	2,539,718	5,062,821	0	173	660,451	2,496,377	11,700,000
$NEWLYVESTING_{t+1}$	6,730	3,626,232	6,372,761	0	310,737	1,257,137	3,917,051	15,900,000
$UNVESTEDSTOCK_t$	6,730	3,746,586	7,785,361	0	0	792,389	3,645,577	17,700,000
$UNVESTEDOPTION_t$	6,730	5,339,176	10,300,000	0	0	1,370,083	5,440,901	24,500,000
$UNVESTED_t$	6,730	9,337,752	15,700,000	0	841,833	3,341,484	10,400,000	39,500,000
$UNVESTEDADJ_t$	6,730	5,656,486	10,200,000	0	346,113	1,835,151	6,132,905	25,000,000
$ALREADYVESTEDSTOCK_t$	6,730	55,900,000	191,000,000	72,775	1,629,998	6,123,997	22,800,000	244,000,000
$ALREADYVESTEDOPTION_t$	6,730	12,600,000	25,900,000	0	288,680	2,828,472	11,900,000	60,400,000
$ALREADYVESTED_t$	6,730	70,400,000	205,000,000	415,985	4,156,739	13,300,000	43,500,000	298,000,000
$MMRATIO_t$	6,167	0.431	0.246	0.060	0.273	0.392	0.536	1.000
$MMRATIOALL_t$	6,710	0.116	0.116	0.000	0.024	0.090	0.167	0.336
Stock sold								
$STOCKSOLD_{t+1}$	6,730	4,098,075	11,200,000	0	0	288,069	2,659,125	19,800,000

Table 1(Cont'd)
Panel B

Variable	N	Mean	SD	5%	25%	Median	75%	95%
Change in investment								
ΔRD_{t+1}	6,730	0.003	0.029	-0.017	0.000	0.000	0.002	0.037
$\Delta RDAD_{t+1}$	6,730	0.004	0.032	-0.023	0.000	0.000	0.004	0.044
$\Delta CAPEX_{t+1}$	6,730	0.002	0.043	-0.056	-0.009	0.000	0.010	0.061
$\Delta RDADCAPEX_{t+1}$	6,730	0.006	0.065	-0.080	-0.013	0.002	0.019	0.105
$\Delta CAPEXALL_{t+1}$	6,730	0.006	0.106	-0.123	-0.023	0.000	0.024	0.153
$\Delta RDADCAPEXALL_{t+1}$	6,730	0.010	0.123	-0.146	-0.027	0.002	0.034	0.188
Control variables								
Q_{t+1}	6,730	1.848	1.720	0.470	0.835	1.287	2.141	5.358
Q_t	6,730	2.017	2.024	0.470	0.868	1.372	2.333	5.868
MV_t	6,730	6.896	1.599	4.510	5.779	6.712	7.901	9.897
$MOMENTUM_t$	6,730	0.098	0.540	-0.552	-0.220	0.000	0.275	1.072
AGE_t	6,730	2.841	0.731	1.609	2.398	2.773	3.401	4.060
$CASH_t$	6,730	0.204	0.219	0.006	0.040	0.120	0.295	0.688
$BOOKLEV_t$	6,730	0.215	0.218	0.000	0.013	0.173	0.330	0.645
$RETEARN_t$	6,730	-0.191	1.362	-2.403	-0.144	0.163	0.389	0.724
ROA_t	6,730	0.005	0.179	-0.374	-0.012	0.046	0.090	0.190
$SALARY_t$	6,730	670,194	336,489	265,000	429,577	600,000	860,833	1,300,000
$BONUS_t$	6,730	167,704	483,780	0	0	0	58,000	979,620

This panel reports the summary statistics of the main variables used in our multivariate analysis. All variables are winsorized at 1% and 99% level. Variable definitions are listed in Appendix A.

Table 2: The relationship between the change in investment and equity incentives, including newly-vesting securities, unvested securities, and already-vested securities separately

Panel A: Baseline specifications

Dependent Variables	(1) ΔRD_{t+1}	(2) $\Delta RDAD_{t+1}$	(3) $\Delta CAPEX_{t+1}$	(4) $\Delta RDAD\text{-}CAPEX_{t+1}$	(5) $\Delta CAPEX\text{-}ALL_{t+1}$	(6) $\Delta RDAD\text{-}CAPEXALL_{t+1}$
$NEWLYVESTING_{t+1}$	**-0.309****	**-0.391****	**-0.205**	**-0.707****	**-1.395*****	**-2.154*****
	(0.148)	(0.165)	(0.183)	(0.285)	(0.513)	(0.616)
$UNVESTEDADJ_t$	-0.034	-0.053	0.000	-0.093	0.514	0.478
	(0.055)	(0.068)	(0.123)	(0.168)	(0.447)	(0.496)
$ALREADYVESTED_t$	-0.004	-0.002	0.039**	0.035*	0.020	0.016
	(0.005)	(0.006)	(0.017)	(0.018)	(0.037)	(0.042)
Q_{t+1}	0.004***	0.004***	0.006***	0.011***	0.021***	0.026***
	(0.001)	(0.001)	(0.001)	(0.002)	(0.003)	(0.004)
Q_t	0.003***	0.004***	0.000	0.005***	-0.007***	-0.002
	(0.001)	(0.001)	(0.001)	(0.002)	(0.002)	(0.003)
MV_t	-0.005*	-0.005*	0.004	-0.003	-0.005	-0.014
	(0.003)	(0.003)	(0.003)	(0.005)	(0.008)	(0.010)
$MOMENTUM_t$	0.004***	0.004***	0.010***	0.016***	0.020***	0.027***
	(0.001)	(0.002)	(0.002)	(0.003)	(0.005)	(0.006)
AGE_t	-0.017*	-0.017	-0.008	-0.030	0.011	-0.004
	(0.010)	(0.010)	(0.012)	(0.019)	(0.036)	(0.041)
$CASH_t$	0.024**	0.027**	0.089***	0.123***	0.274***	0.315***
	(0.010)	(0.011)	(0.014)	(0.022)	(0.033)	(0.041)
$BOOKLEV_t$	-0.004	-0.006	-0.045***	-0.060***	-0.123***	-0.137***
	(0.010)	(0.011)	(0.014)	(0.021)	(0.043)	(0.049)
$RETEARN_t$	0.008**	0.008**	-0.000	0.009*	-0.007	0.007
	(0.004)	(0.004)	(0.002)	(0.006)	(0.007)	(0.009)
ROA_t	0.027**	0.036***	0.010	0.051**	0.007	0.059*
	(0.013)	(0.014)	(0.011)	(0.022)	(0.027)	(0.035)
$SALARY_t$	0.007	-0.014	-0.084	-0.134	0.011	-0.049
	(0.052)	(0.069)	(0.119)	(0.150)	(0.250)	(0.280)
$BONUS_t$	-0.001	-0.000	0.001	0.005	0.034	0.047
	(0.007)	(0.008)	(0.020)	(0.023)	(0.052)	(0.057)
Intercept	0.073**	0.071**	-0.017	0.078	-0.038	0.051
	(0.030)	(0.032)	(0.036)	(0.055)	(0.109)	(0.126)
Observations	6,730	6,730	6,730	6,730	6,730	6,730
Adjusted R^2	0.403	0.425	0.320	0.406	0.233	0.273

This panel reports the ordinary least squares ("OLS") regression results on the relationship between the CEO's vesting equity and investment. Variable definitions are listed in Appendix A. *NEWLYVESTING*, *UNVESTEDADJ*, and *ALREADYVESTED* are in billions, and *SALARY* and *BONUS* are in ten millions. Standard errors are in parentheses, adjusted for heteroskedasticity and clustered by firm. Year and firm fixed effects are included in all columns. *** (**) (*) indicates significance at the 1% (5%) (10%) two-tailed level, respectively.

Table 2 (Cont'd)

Panel B: Changes-in-changes specifications

Dependent Variables	(1) ΔRD_{t+1}	(2) $\Delta RDAD_{t+1}$	(3) $\Delta CAPEX_{t+1}$	(4) $\Delta RDAD\text{-}CAPEX_{t+1}$	(5) $\Delta CAPEX\text{-}ALL_{t+1}$	(6) $\Delta RDAD\text{-}CAPEXALL_{t+1}$
$\Delta NEWLYVESTING_{t+1}$	**-0.339****	**-0.378*****	**-0.159**	**-0.632****	**-1.488*****	**-2.091*****
	(0.141)	(0.142)	(0.192)	(0.262)	(0.536)	(0.609)
$\Delta UNVESTEDADJ_t$	-0.054	-0.099*	-0.185	-0.305**	-0.601*	-0.744*
	(0.049)	(0.056)	(0.113)	(0.145)	(0.361)	(0.394)
$\Delta ALREADYVESTED_t$	-0.006	-0.002	0.039**	0.034*	0.052	0.047
	(0.006)	(0.006)	(0.016)	(0.020)	(0.043)	(0.046)
ΔQ_{t+1}	0.000	0.000	0.003***	0.005***	0.013***	0.014***
	(0.001)	(0.001)	(0.001)	(0.002)	(0.003)	(0.003)
ΔQ_t	0.001	0.001	0.001	0.002	0.001	0.002
	(0.001)	(0.001)	(0.001)	(0.002)	(0.002)	(0.002)
ΔMV_t	0.005*	0.006**	0.015***	0.022***	0.001	0.009
	(0.003)	(0.003)	(0.003)	(0.005)	(0.008)	(0.009)
$\Delta MOMENTUM_t$	0.000	-0.000	-0.001	-0.000	0.014***	0.015***
	(0.001)	(0.001)	(0.002)	(0.003)	(0.005)	(0.005)
$\Delta CASH_t$	0.003	0.003	0.038***	0.040**	0.156***	0.172***
	(0.009)	(0.010)	(0.011)	(0.018)	(0.028)	(0.034)
$\Delta BOOKLEV_t$	-0.005	-0.003	-0.046***	-0.063***	-0.128***	-0.122***
	(0.011)	(0.012)	(0.013)	(0.022)	(0.033)	(0.040)
$\Delta RETEARN_t$	0.005	0.007	-0.003	0.004	-0.002	0.013
	(0.004)	(0.005)	(0.004)	(0.007)	(0.008)	(0.013)
ΔROA_t	0.011	0.015*	0.000	0.020	-0.011	0.022
	(0.008)	(0.009)	(0.010)	(0.015)	(0.022)	(0.025)
$\Delta SALARY_t$	-0.041	0.016	-0.030	-0.041	-0.416	-0.398
	(0.104)	(0.136)	(0.216)	(0.281)	(0.469)	(0.545)
$\Delta BONUS_t$	-0.011	-0.003	0.014	0.013	0.133**	0.142**
	(0.007)	(0.009)	(0.028)	(0.033)	(0.061)	(0.065)
Intercept	0.006***	0.006***	0.011***	0.019***	0.011**	0.016***
	(0.001)	(0.001)	(0.002)	(0.003)	(0.005)	(0.006)
Observations	4,378	4,378	4,378	4,378	4,378	4,378
Adjusted R^2	0.493	0.513	0.397	0.468	0.326	0.368

This panel reports the OLS regression results on the relationship between the CEO's vesting equity and investment. Variable definitions are listed in Appendix A. *NEWLYVESTING*, *UNVESTEDADJ*, and *ALREADYVESTED* are in billions, and *SALARY* and *BONUS* are in ten millions. The prefix Δ denotes the change from year *t-1* to *t* for variables with subscript *t* and from year *t* to *t+1* for variables with subscript *t+1*. Standard errors are in parentheses, adjusted for heteroskedasticity and clustered by firm. Year and firm fixed effects are included in all columns. *** (**) (*) indicates significance at the 1% (5%) (10%) two-tailed level, respectively.

Table 3: The relationship between change in investment and equity incentive ratios

Panel A: Measuring CEO incentives as the ratio of newly-vesting securities to the sum of newly-vesting securities and unvested securities

Dependent Variables	(1) ΔRD_{t+1}	(2) $\Delta RDAD_{t+1}$	(3) $\Delta CAPEX_{t+1}$	(4) $\Delta RDAD\text{-}CAPEX_{t+1}$	(5) $\Delta CAPEX\text{-}ALL_{t+1}$	(6) $\Delta RDAD\text{-}CAPEXALL_{t+1}$
$MMRATIO_t$	**-0.006****	**-0.007*****	**0.002**	**-0.007**	**-0.004**	**-0.017**
	(0.003)	(0.003)	(0.004)	(0.006)	(0.012)	(0.013)
Q_{t+1}	0.003***	0.004***	0.006***	0.011***	0.021***	0.026***
	(0.001)	(0.001)	(0.001)	(0.002)	(0.003)	(0.004)
Q_t	0.003***	0.003***	0.000	0.004**	-0.008***	-0.003
	(0.001)	(0.001)	(0.001)	(0.002)	(0.002)	(0.003)
MV_t	-0.007**	-0.007**	0.005*	-0.004	-0.005	-0.018
	(0.003)	(0.003)	(0.003)	(0.005)	(0.009)	(0.011)
$MOMENTUM_t$	0.004**	0.004***	0.010***	0.017***	0.019***	0.027***
	(0.002)	(0.002)	(0.002)	(0.003)	(0.005)	(0.006)
AGE_t	-0.020*	-0.019	-0.010	-0.034*	0.013	-0.003
	(0.011)	(0.012)	(0.012)	(0.020)	(0.039)	(0.045)
$CASH_t$	0.019*	0.023*	0.089***	0.119***	0.268***	0.304***
	(0.011)	(0.012)	(0.015)	(0.023)	(0.035)	(0.043)
$BOOKLEV_t$	-0.011	-0.013	-0.037***	-0.058***	-0.100**	-0.120**
	(0.010)	(0.011)	(0.014)	(0.021)	(0.045)	(0.050)
$RETEARN_t$	0.009**	0.009**	0.000	0.011*	-0.001	0.017*
	(0.004)	(0.004)	(0.002)	(0.006)	(0.007)	(0.009)
ROA_t	0.033**	0.041***	0.009	0.057***	0.012	0.077**
	(0.013)	(0.014)	(0.011)	(0.021)	(0.028)	(0.035)
$SALARY_t$	0.011	0.018	-0.065	-0.077	-0.150	-0.184
	(0.051)	(0.062)	(0.128)	(0.150)	(0.263)	(0.285)
$BONUS_t$	-0.006	-0.004	0.003	0.002	0.051	0.060
	(0.007)	(0.008)	(0.021)	(0.024)	(0.055)	(0.060)
Intercept	0.097***	0.094***	-0.022	0.101*	-0.037	0.088
	(0.033)	(0.035)	(0.037)	(0.059)	(0.118)	(0.135)
Observations	6,167	6,167	6,167	6,167	6,167	6,167
Adjusted R^2	0.411	0.437	0.332	0.419	0.245	0.289

This panel reports the OLS regression results on the relationship between the CEO's vesting equity (measured using *MMRATIO*) and investment. Variable definitions are listed in Appendix A. *SALARY* and *BONUS* are in ten millions. Standard errors are in parentheses, adjusted for heteroskedasticity and clustered by firm. Year and firm fixed effects are included in all columns. *** (**) (*) indicates significance at the 1% (5%) (10%) two-tailed level, respectively.

Table 3 (Cont'd)

Panel B: Measuring CEO incentives as the ratio of newly-vesting securities to the sum of newly-vesting securities, unvested securities, and already-vested securities

Dependent Variables	(1) ΔRD_{t+1}	(2) $\Delta RDAD_{t+1}$	(3) $\Delta CAPEX_{t+1}$	(4) $\Delta RDAD\text{-}CAPEX_{t+1}$	(5) $\Delta CAPEX\text{-}ALL_{t+1}$	(6) $\Delta RDAD\text{-}CAPEXALL_{t+1}$
$MMRATIOALL_t$	**-0.019****	**-0.021****	**-0.003**	**-0.029****	**-0.014**	**-0.054**
	(0.008)	(0.008)	(0.009)	(0.015)	(0.030)	(0.035)
Q_{t+1}	0.003***	0.004***	0.006***	0.011***	0.021***	0.026***
	(0.001)	(0.001)	(0.001)	(0.002)	(0.003)	(0.004)
Q_t	0.003***	0.003***	0.000	0.005***	-0.008***	-0.002
	(0.001)	(0.001)	(0.001)	(0.002)	(0.002)	(0.003)
MV_t	-0.006**	-0.006**	0.005*	-0.003	-0.005	-0.015
	(0.003)	(0.003)	(0.003)	(0.005)	(0.008)	(0.010)
$MOMENTUM_t$	0.004***	0.004***	0.010***	0.016***	0.019***	0.027***
	(0.001)	(0.002)	(0.002)	(0.003)	(0.005)	(0.006)
AGE_t	-0.017*	-0.017*	-0.011	-0.033*	0.006	-0.010
	(0.010)	(0.010)	(0.012)	(0.019)	(0.036)	(0.042)
$CASH_t$	0.024**	0.027**	0.088***	0.122***	0.272***	0.313***
	(0.010)	(0.011)	(0.014)	(0.022)	(0.033)	(0.042)
$BOOKLEV_t$	-0.004	-0.007	-0.045***	-0.061***	-0.121***	-0.134***
	(0.010)	(0.011)	(0.014)	(0.021)	(0.043)	(0.049)
$RETEARN_t$	0.008**	0.008**	-0.000	0.009	-0.007	0.007
	(0.004)	(0.004)	(0.002)	(0.006)	(0.007)	(0.009)
ROA_t	0.027**	0.036***	0.010	0.051**	0.008	0.060*
	(0.013)	(0.014)	(0.011)	(0.022)	(0.027)	(0.035)
$SALARY_t$	-0.018	-0.045	-0.073	-0.163	-0.033	-0.152
	(0.051)	(0.070)	(0.118)	(0.150)	(0.250)	(0.281)
$BONUS_t$	-0.001	0.001	0.001	0.006	0.037	0.052
	(0.007)	(0.008)	(0.020)	(0.023)	(0.052)	(0.057)
Intercept	0.081***	0.081**	-0.015	0.093*	-0.025	0.083
	(0.030)	(0.032)	(0.036)	(0.055)	(0.109)	(0.125)
Observations	6,710	6,710	6,710	6,710	6,710	6,710
Adjusted R^2	0.404	0.426	0.317	0.405	0.232	0.272

This panel reports the OLS regression results on the relationship between the CEO's vesting equity (measured using *MMRATIOALL*) and investment. Variable definitions are listed in Appendix A. *SALARY* and *BONUS* are in ten millions. Standard errors are in parentheses, adjusted for heteroskedasticity and clustered by firm. Year and firm fixed effects are included in all columns. *** (**) (*) indicates significance at the 1% (5%) (10%) two-tailed level, respectively.

Table 4
Panel A: Correlations between the actual sale of securities and the newly-vesting securities

Pearson / Spearman	(i)	(ii)	(iii)	(iv)
(i) $STOCKSOLD_{t+1}$		0.258***	0.330***	**0.377***
(ii) $NEWLYVESTINGSTOCK_{t+1}$	0.363***		0.179***	0.600***
(iii) $NEWLYVESTINGOPTION_{t+1}$	0.240***	0.279***		0.923***
(iv) $NEWLYVESTING_{t+1}$	**0.393***	0.559***	0.822***	

This panel reports Pearson and Spearman correlations between the equity sales ($STOCKSOLD_{t+1}$) and equity vesting ($NEWLYVESTINGSTOCK_{t+1}$, $NEWLYVESTINGOPTION_{t+1}$, and $NEWLYVESTING_{t+1}$). Variable definitions are listed in Appendix A. Pearson (Spearman) correlations are reported above (below) the main diagonal. *** (**) (*) indicates significance at the 1% (5%) (10%) level.

Table 4 (Cont'd)

Panel B: The relationship between change in investment and the sale of securities, with the newly-vesting securities *NEWLYVESTING* as an IV for the sale of securities

Dependent Variables	(1) $STOCK\text{-}SOLD_{t+1}$	(2.1) ΔRD_{t+1}	(2.2) $\Delta RDAD_{t+1}$	(2.3) $\Delta CAPEX_{t+1}$	(2.4) $\Delta RDAD\text{-}CAPEX_{t+1}$	(2.5) $\Delta CAPEX\text{-}ALL_{t+1}$	(2.6) $\Delta RDADCAP\text{-}EXALL_{t+1}$
$NEWLYVESTING_{t+1}$	**0.328*****						
	(0.034)						
$FIT\_STOCKSOLD_{t+1}$		**-0.942***	**-1.192***	**-0.625**	**-2.154****	**-4.252****	**-6.564****
		(0.553)	(0.635)	(0.585)	(1.083)	(1.918)	(2.631)
$UNVESTEDADJ_t$	-0.022	-0.054	-0.078	-0.013	-0.139	0.422	0.337
	(0.025)	(0.073)	(0.089)	(0.123)	(0.193)	(0.492)	(0.593)
$ALREADYVESTED_t$	0.018***	0.013	0.020	0.050**	0.074**	0.098*	0.136*
	(0.002)	(0.014)	(0.016)	(0.023)	(0.033)	(0.059)	(0.078)
Q_{t+1}	0.001***	0.004***	0.005***	0.006***	0.012***	0.024***	0.031***
	(0.000)	(0.001)	(0.001)	(0.001)	(0.002)	(0.004)	(0.005)
Q_t	0.000*	0.003***	0.004***	0.000	0.005***	-0.007***	-0.001
	(0.000)	(0.001)	(0.001)	(0.001)	(0.002)	(0.002)	(0.003)
MV_t	0.000	-0.006**	-0.005*	0.004	-0.004	-0.007	-0.017*
	(0.000)	(0.003)	(0.003)	(0.003)	(0.005)	(0.008)	(0.010)
$MOMENTUM_t$	0.001**	0.005***	0.005***	0.010***	0.018***	0.022***	0.031***
	(0.000)	(0.002)	(0.002)	(0.002)	(0.003)	(0.005)	(0.006)
AGE_t	-0.002	-0.019*	-0.019*	-0.010	-0.034*	0.002	-0.017
	(0.002)	(0.010)	(0.011)	(0.012)	(0.019)	(0.037)	(0.044)
$CASH_t$	0.000	0.024**	0.027**	0.089***	0.123***	0.274***	0.315***
	(0.002)	(0.011)	(0.011)	(0.014)	(0.022)	(0.034)	(0.043)
$BOOKLEV_t$	0.001	-0.003	-0.005	-0.044***	-0.058***	-0.118***	-0.129**
	(0.002)	(0.010)	(0.011)	(0.014)	(0.022)	(0.044)	(0.050)
$RETEARN_t$	0.001**	0.009**	0.009**	0.000	0.011**	-0.004	0.012
	(0.000)	(0.004)	(0.004)	(0.002)	(0.006)	(0.007)	(0.010)
ROA_t	-0.001	0.026**	0.034**	0.009	0.048**	0.002	0.052
	(0.001)	(0.013)	(0.014)	(0.011)	(0.022)	(0.027)	(0.036)
$SALARY_t$	0.073***	0.076	0.073	-0.038	0.024	0.321	0.430
	(0.016)	(0.078)	(0.097)	(0.133)	(0.199)	(0.326)	(0.417)
$BONUS_t$	0.002	0.000	0.002	0.002	0.009	0.041	0.058
	(0.004)	(0.009)	(0.010)	(0.020)	(0.026)	(0.058)	(0.068)
Intercept	0.003	0.037**	0.035**	-0.020	0.027	-0.009	0.044
	(0.009)	(0.014)	(0.015)	(0.016)	(0.026)	(0.049)	(0.058)
Observations	6,730	6,730	6,730	6,730	6,730	6,730	6,730
Adjusted R^2 (R^2)	0.421	0.354	0.359	0.304	0.343	0.159	0.138

This panel reports the 2SLS regression results on the relationship between CEO equity sales and investment, using *NEWLYVESTING* as an instrumental variable for *STOCKSOLD*. Column (1) presents the first-stage regression results, and columns (2.1)-(2.6) present the second-stage regression results for the six different investment measures. Variable definitions are listed in Appendix A. *FIT_STOCKSOLD* is the fitted value of *STOCKSOLD* from the first-stage regressions. *STOCKSOLD*, *NEWLYVESTING*, *UNVESTEDADJ*, and *ALREADYVESTED* are in billions, and *SALARY* and *BONUS* are in ten millions. Standard errors are in parentheses, adjusted for heteroskedasticity and clustered by firm. Year and firm fixed effects are included in all columns. *** (**) (*) indicates significance at the 1% (5%) (10%) two-tailed level, respectively.

Table 5: The relationship between the likelihood of meeting/beating analyst consensus forecast and equity incentives

Dependent Variables	(1) $BEAT_{t+1}$	(2) $BEAT\text{-}BELOW1_{t+1}$	(3) $BEAT\text{-}ABOVE1_{t+1}$	(4) $BEAT\text{-}BELOW1_{t+1}$	(5) $BEAT\text{-}ABOVE1_{t+1}$
$NEWLYVESTING_{t+1}$	**5.566***	**6.705****	**-0.173**		
	(3.021)	(3.262)	(2.953)		
	[1.878*]	[1.263**]	[-0.068]		
$NEWLYVESTINGSTOCK_{t+1}$				**8.834**	**3.194**
				(9.455)	(7.247)
				[1.664]	[1.246]
$NEWLYVESTINGOPTION_{t+1}$				**6.936***	**-1.093**
				(3.743)	(3.456)
				[1.307*]	[-0.426]
$UNVESTEDADJ_t$	2.596	3.228	0.045***	3.220	-0.450
	(2.002)	(2.093)	(0.016)	(2.091)	(1.955)
$ALREADYVESTED_t$	-0.107	-0.174	-0.052***	-0.167	0.005
	(0.075)	(0.107)	(0.008)	(0.106)	(0.085)
MV_t	0.018	-0.049**	0.248***	-0.050**	0.045***
	(0.017)	(0.020)	(0.090)	(0.021)	(0.016)
Q_t	-0.035***	0.031***	-0.022	0.032***	-0.052***
	(0.008)	(0.009)	(0.023)	(0.009)	(0.008)
ROA_t	0.480***	0.384***	0.234***	0.384***	0.249***
	(0.088)	(0.117)	(0.062)	(0.117)	(0.090)
AGE_t	-0.027	-0.001	0.106***	-0.001	-0.022
	(0.024)	(0.028)	(0.036)	(0.028)	(0.023)
$INSTIPCT_t$	0.176***	-0.147**	0.090***	-0.147**	0.234***
	(0.063)	(0.072)	(0.035)	(0.072)	(0.062)
ALY_N_{t+1}	0.152***	0.049	-0.042***	0.049	0.106***
	(0.036)	(0.044)	(0.015)	(0.044)	(0.036)
$HORIZON_{t+1}$	0.018	-0.123***	0.806***	-0.122***	0.091***
	(0.033)	(0.047)	(0.024)	(0.047)	(0.035)
ALY_DISP_{t+1}	-0.092***	-0.121***	-1.242***	-0.121***	-0.042***
	(0.015)	(0.029)	(0.195)	(0.029)	(0.015)
$POSUE_{t+1}$	0.924***	0.040	-0.457	0.039	0.805***
	(0.025)	(0.029)	(1.948)	(0.029)	(0.024)
Intercept	-0.461**	-0.277	0.002	-0.272	-1.243***
	(0.190)	(0.257)	(0.086)	(0.258)	(0.196)
Observations	17,173	17,173	17,173	17,173	17,173
Pseudo R^2	0.126	0.027	0.091	0.027	0.091

This panel reports the probit regression results on the relationship between the CEO's vesting equity and the likelihood of beating the quarterly analyst consensus forecast. Variable definitions are listed in Appendix A. *NEWLYVESTING*, *NEWLYVESTINGSTOCK*, *NEWLYVESTINGOPTION*, *UNVESTEDADJ*, and *ALREADYVESTED* are in billions. Standard errors are in parentheses, adjusted for heteroskedasticity and clustered by firm. For *NEWLYVESTING*, *NEWLYVESTINGSTOCK*, and *NEWLYVESTINGOPTION*, the marginal effects (dF/dx) are displayed below the standard errors. Year and industry fixed effects are included in all columns but the coefficient estimates are not reported. *** (**) (*) indicates significance at the 1% (5%) (10%) two-tailed level, respectively.

Table 6: The relationship between earnings announcement returns and equity incentives

Dependent Variables	(1)	(2)	(3)
		CAR (-1, +1)	
TERC. NEWLYVESTING $_{t+1}$	**-0.167**	**-0.278****	**0.545****
	(0.139)	(0.137)	(0.212)
TERC. NEWLYVESTING $_{t+1}$ **×** ***BEAT*** $_{t+1}$			**-1.215*****
			(0.230)
TERC. UNVESTEDADJ $_t$	0.198	0.080	0.093
	(0.140)	(0.134)	(0.133)
TERC. ALREADYVESTED $_t$	0.170	0.102	0.106
	(0.113)	(0.106)	(0.106)
DIF_{t+1}		0.332	0.314
		(0.292)	(0.284)
BEAT $_{t+1}$		6.358***	7.603***
		(0.203)	(0.351)
MV_t	-0.193**	-0.386***	-0.377***
	(0.081)	(0.081)	(0.081)
Q_t	-0.049	0.012	0.010
	(0.057)	(0.054)	(0.054)
$LEVERAGE_t$	1.549***	1.964***	1.937***
	(0.440)	(0.421)	(0.420)
PASTRET(1Y)	-0.004	-0.009***	-0.009***
	(0.003)	(0.003)	(0.003)
PASTRET(1M)	0.017	0.002	0.001
	(0.011)	(0.010)	(0.010)
FYE	0.148	0.375*	0.383*
	(0.208)	(0.205)	(0.205)
ANNRET(LAG1)	-0.016	-0.030***	-0.031***
	(0.010)	(0.010)	(0.010)
ANNRET(LAG2)	-0.017*	-0.024***	-0.025***
	(0.010)	(0.009)	(0.009)
ANNRET(LAG3)	-0.007	-0.008	-0.009
	(0.009)	(0.009)	(0.009)
ANNRET(LAG4)	0.010	0.009	0.009
	(0.009)	(0.008)	(0.008)
Intercept	-0.352	-2.651*	-3.436**
	(1.610)	(1.568)	(1.559)
Observations	18,686	18,686	18,686
Adjusted R^2	0.007	0.087	0.089

The table shows regressions of cumulative market adjusted returns over days -1 to +1 around the quarterly earnings announcements in year t+1 in percent (CAR_{t+1}). Variable definitions are in Appendix A. *TERC. NEWLYVESTING*, *UNVESTEDADJ*, and *ALREADYVESTED* are tercile ranks 0-2 for the vesting variables. Standard errors are in parentheses, clustered by announcement day. Industry fixed effects are included in all columns but the coefficient estimates are not reported. *** (**) (*) indicates significance at the 1% (5%) (10%) two-tailed level, respectively.

Fig. 1: The frequency of earnings surprises around the analyst forecast for high and low *NEWLYVESTING* firms



This figure illustrates the frequency of earnings surprises of different magnitudes separately for firms with *NEWLYVESTING* in the top tercile of the sample (T3) and firms with *NEWLYVESTING* in the bottom tercile of the sample (T1). The y-axis reports the number of firm-quarters (within T1 and T3) in which the reported EPS exceeds (or falls below) the analyst mean consensus forecast as indicated by the x-axis.

References

Abarbanell, Jeffery S. and Victor Bernard (1992): "Tests of analysts' overreaction/underreaction to earnings information as an explanation for anomalous stock price behavior." *Journal of Finance* 47, 1181-1207.

Asker, John, Joan Farre-Mensa, and Alexander Ljungqvist (2013): "Comparing the investment behavior in public and private firms." Working paper, New York University.

Bartov, Eli, Dan Givoly, and Carla Hayn (2002), "The rewards to meeting or beating earnings expectations." *Journal of Accounting and Economics* 33, 173-204.

Bebchuk, Lucian A. and Lars Stole (1993): "Do short-term objectives lead to under- or overinvestment in long-term projects?" *Journal of Finance* 48, 719–729.

Benmelech, Efraim, Eugene Kandel, and Pietro Veronesi (2010): "Stock-based compensation and CEO (dis)incentives." *Quarterly Journal of Economics* 125, 1769–1820.

Bergstresser, Daniel and Thomas Philippon (2006): "CEO incentives and earnings management." *Journal of Financial Economics* 80, 511–529.

Bettis, Carr, John Bizjak, Jeffrey Coles, and Swaminathan Kalpathy (2010): "Stock and option grants with performance-based vesting provisions." *Review of Financial Studies* 23, 3849–3888.

Bhojraj, Sanjeev, Paul Hribar, Marc Picconi, and John McInnis (2009): "Making sense of cents: an examination of firms that marginally miss or beat analyst forecasts." *Journal of Finance* 64, 2361-2388.

Bizjak, John, James Brickley and Jeffrey Coles (1993): "Stock-based incentive compensation and investment behavior." *Journal of Accounting and Economics* 16, 349–372.

Bushee, Brian J. (1998): "The influence of institutional investors on myopic R&D investment behavior." *Accounting Review* 73, 305–333.

Chan, Louis, Josef Lakonishok, and Theodore Sougiannis (2001): "The stock market valuation of research and development expenditures." *Journal of Finance* 56, 2431–2456.

Cheng, Qiang, and Terry D. Warfield (2005): "Equity incentives and earnings management." *Accounting Review* 80, 441–476.

Cohen, Lauren, Karl Diether, and Christopher Malloy (2013): "Misvaluing innovation." *Review of Financial Studies*, forthcoming.

Davis, Larry R., Billy S. Soo, and Gregory M. Trompeter (2009): "Auditor tenure and the ability to meet or beat earnings forecasts." *Contemporary Accounting Research* 26, 517–548.

Edmans, Alex (2009): "Blockholder trading, market efficiency, and managerial myopia." *Journal of Finance* 64, 2481–2513.

Edmans, Alex, Xavier Gabaix, Tomasz Sadzik, and Yuliy Sannikov (2012): "Dynamic CEO compensation." *Journal of Finance* 67, 1603–1647.

Erickson, Merle, Michelle Hanlon, and Edward L. Maydew (2006): "Is there a link between executive equity incentives and accounting fraud?" *Journal of Accounting Research* 44, 113–143.

Gopalan, Radhakrishnan, Todd T. Milbourn, Fenghua Song, and Anjan V. Thakor (2013): "Duration of executive compensation." *Journal of Finance*, forthcoming.

Goldman, Eitan and Steve Slezak (2006): "An equilibrium model of incentive contracts in the presence of information manipulation." *Journal of Financial Economics* 80, 603–626.

Graham, John R., Campbell R. Harvey, and Shivaram Rajgopal (2005): "The economic implications of corporate financial reporting." *Journal of Accounting and Economics* 40, 3–73.

Hall, Brian and Jeffrey Liebman (1998): "Are CEOs really paid like bureaucrats?" *Quarterly Journal of Economics* 113, 653-691.

Himmelberg, Charles P., R. Glenn Hubbard, and Darius Palia (1999): "Understanding the determinants of managerial ownership and the link between ownership and performance." *Journal of Financial Economics* 53, 353-384.

Jensen, Michael C. and Kevin J. Murphy (1990): "Performance and top-management incentives." *Journal of Political Economy* 98, 225–264.

Johnson, Shane, Harley E. Ryan, and Yisong Tian (2009): "Managerial incentives and corporate fraud: The source of incentives matter." *Review of Finance* 13, 115–145.

Kole, Stacey (1997): "The complexity of compensation contracts." *Journal of Financial Economics* 43, 79–104.

Ladika, Tomislav and Zacharias Sautner (2013): "The effect of managerial short-termism on corporate investment." Working paper, University of Amsterdam.

Laux, Volker (2012): "Stock option vesting conditions, CEO turnover, and myopic investment." *Journal of Financial Economics* 106, 513–526.

Matsumoto, Dawn (2002): "Management's incentives to avoid negative earnings surprises." *Accounting Review* 77, 483–514.

McConnell, John J. and Christopher J. Muscarella (1985): “Corporate capital expenditure decisions and the market value of the firm.” *Journal of Financial Economics* 14, 399–422.

Miller, Merton and Kevin Rock (1985): “Dividend policy under asymmetric information.” *Journal of Finance* 40, 1031-1051.

Narayanan, M. P. (1985): “Managerial incentives for short-term results.” *Journal of Finance* 40, 1469-1484.

Peng, Lin, and Ailsa Roell (2008): “Executive pay, earnings manipulation and shareholder litigation.” *Review of Finance* 12, 141–184.

Porter, Michael (1992): “Capital disadvantage: America’s failing capital investment system.” *Harvard Business Review* 70, 65–82.

Savor, Pavel G. and Mungo I. Wilson (2011): “Earnings announcements and systematic risk.” Working Paper, Temple University.

Shue, Kelly and Richard Townsend (2013): “Swinging for the fences: Executive reactions to quasi-random option grants.” Working paper, University of Chicago.

Skinner, Douglas J. and Richard G. Sloan (2002): “Earnings surprises, growth expectations, and stock returns or don't let an earnings torpedo sink your portfolio.” *Review of Accounting Studies* 7, 289–312.

Stein, Jeremy C. (1988): “Takeover threats and managerial myopia.” *Journal of Political Economy* 46, 61-80.

Stein, Jeremy C. (1989): “Efficient capital markets, inefficient firms: A model of myopic corporate behavior.” *Quarterly Journal of Economics* 104, 655-669.